



**BlueCross BlueShield**  
of Vermont

An Independent Licensee of the Blue Cross and Blue Shield Association.

## Investigational Services and Procedures Corporate Medical Policy

File Name: Investigational Services and Procedures

File Code: 10.01.VT204

Origination: 09/2016

Last Review: 07/2024

Next Review: 10/2025

Effective Date: 10/01/2024

### Description

Attachment (I) outlines current services and/or procedure(s) considered to be investigational by Blue Cross Blue Shield of Vermont (BCBSVT).

### Definition of Investigational

“Experimental or Investigational Services” means health care items or services that are either not generally accepted by informed health care providers in the United States as effective in treating a condition, illness, or diagnosis for which their use is proposed, or are not proven by medical or scientific evidence to be effective in treating a condition, illness, or diagnosis.

Technologies are assessed using the following criteria. Any technology that fails to meet ALL the following criteria is considered to be “Investigational”:

1. The technology must have final approval from the appropriate governmental regulatory bodies.
  - This criterion applies to drugs, biological products, devices and any other product or procedure that must have final approval to market from the U.S. Food and Drug Administration (FDA) or any other federal governmental body with authority to regulate the use of the technology.
  - Any approval that is granted as an interim step in the U.S. Food and Drug Administration’s or any other federal governmental body’s regulatory process is not sufficient.
  - The indications for which the technology is approved need not be the same as those which the (BCBSVT) Medical Policy Committee is evaluating.
2. The scientific evidence must permit conclusions concerning the effect of the technology on health outcomes.

- The evidence should consist of well-designed and well-conducted investigations published in peer-reviewed journals. The quality of the body of studies and the consistency of the results are considered in evaluating the evidence.
  - The evidence should demonstrate that the technology can measure or alter the physiological changes related to a disease, injury, illness, or condition. In addition, there should be evidence, or a convincing argument based on established medical facts that such measurement or alteration affects health outcomes.
3. The technology must improve the net health outcome.
    - The technology's beneficial effects on health outcomes should outweigh any harmful effects on health outcomes.
  4. The technology must be as beneficial as any established alternatives.
    - The technology should improve the net health outcome as much as, or more than, established alternatives.
  5. The improvement must be attainable outside the investigational settings.
    - When used under the usual conditions of medical practice, the technology should be reasonably expected to satisfy Criteria #3 and #4.

In reviewing the above criteria, the BCBSVT Medical Policy Committee will consider physician specialty society recommendations, the view of prudent medical practitioners practicing in relevant clinical areas and any other relevant factors.

## Policy

The following is a list of current services and/or procedure(s) which are considered investigational.

### Coding Information

[Attachment I](#)

### Policy Implementation/Update information

06/2020	Policy new Format
10/2020	Coding Updates effective 10/01/2020 Medical Policy: Added codes: 0097U, 0107U, 82239, 82272, 82274, 82542, 82656, 82710, 82715, 82725, 83520, 83630, 83986, 83993, 84311, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89161, 89240 ARE CONSIDERED INVESTIGATIONAL WITH THE FOLLOWING DIAGNOSES CODES: A04.8, A04.9, K58.0, K58.1, K58.2, K58.8, K58.9, K59.8, K63.9, K90.89. Coding Updates effective 10/01/2020 via Adaptive Maintenance Cycle:

	Added codes: 0016M, 0203U, 0204U, 0205U, 0206U, 0207U, 0208U, 0209U, 0211U, 0216U, 0217U, 0218U, 0219U, 0220U, 0225U, K1006, K1007, K1010, K1011, K1012, Q4249, Q4250, Q4254, Q4255.
01/2021	Coding Updates effective 01/01/2021 Adaptive Maintenance Cycle: Changed effective date to 01/01/2021 Removed Codes 38230, 83993, 90694 Updated Codes 82172 & 84181 to Investigational for All diagnoses Updated Codes 64910, 64911, 64912, 64913 as Investigational with dx codes C61, N52.0-N52.9 Added codes 0227U, 0228U, 0229U, 0620T, 0621T, 0622T, 0623T, 0624T, 0625T, 0626T, 0627T, 0628T, 0629T, 0630T, 0631T, 0632T, 0633T, 0634T, 0635T, 0636T, 0637T, 0638T, 0639T, 22869, 22870, 30468, 55880, 57465, 81514, 92229, C1825, C9771, C9772, C9773, C9774, C9775 Deleted codes 0400T, 0401T Removed codes 38206, 38230, 38241 codes require PA
04/2021	Coding Updates effective 04/01/2021 Adaptive Maintenance Cycle: Added codes: C9776, C9777, J3490, K1016, K1017, K1018, K1019, K1020, S1091, 0242U, 0243U, 0244U, 0247U. Removed codes: K1010, K1011, K1012, 64451, 78803, 78830, 78831, 78832, 78835
05/2021	Coding Update effective 05/01/2021: Added codes 81518, 0045U, 0153U.
07/2021	Coding Updates effective 07/01/2021: 0248U, 0249U, 0250U, 0251U, 0252U, 0253U, 0640T, 0641T, 0642T, 0643T, 0645T, 0646T, 0647T, 0648T, 0649T, 0652T, 0653T, 0654T, 0655T, 0656T, 0657T, 0658T, 0659T, 0660T, 0661T, 0664T, 0665T, 0666T, 0667T, 0668T, 0669T, 0670T, A9593, A9594, G0327, 58674, 90626, 90627, 90671, 90677, 90758, C1761
08/2021	Coding Updates effective 08/01/2021: Added codes E1700, E1701, E1702
09/2021	Coding update effective 09/01/2021: Removed code 53854
10/2021	Coding update effective 10/01/2021: Added Codes 0255U, 0258U, 0259U, 0260U, 0261U, 0262U, 0263U, 0264U, 0266U, 0267U, 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, 0018M, Deleted code 0139U. Revised 0051U descriptor. Added HCPCS Codes: C1831, C9780, K1023, K1024, K1025, K1026, Q4251, Q4252, Q4253
11/2021	Coding update effective 11/01/2021 (To Align Corporate Bioengineered Skin Medical Policy Table): Added codes C9354, C9356, C9358, C9360, C9363, C9364, Q4103, Q4104, Q4110, Q4111, Q4112, Q4113, Q4115, Q4117, Q4118, Q4121, Q4123, Q4124, Q4125, Q4126, Q4127, Q4130, Q4134, Q4135, Q4136, Q4141, Q4142, Q4143, Q4146, Q4147, Q4149, Q4152, Q4158, Q4161, Q4164, Q4165, Q4166, Q4167, Q4179, Q4182, Q4193, Q4196, Q4200, Q4202, Q4203, Q4222. Removed codes: Q4185, Q4189, Q4192, Q4249, Q4250, Q4254, Q4255.
12/2021	Coding update effective 12/01/2021: Added code G9143
12/2021	Coding Update Effective 01/01/2022 (Adaptive Maintenance Cycle): Deleted the following codes: 0548T, 0549T, 0550T, 0551T, C9752, C9753, 95943, 0208U Codes Added: 33370, 42975, 43497, 53451, 53452, 53453, 53454, 61736, 61737, 64628, 64629, 81560, 90759. Added codes PLA: 0285U, 0288U, 0289U, 0290U, 0291U, 0292U, 0293U, 0294U, 0295U, 0296U, 0297U, 0298U, 0299U, 0300U, 0303U, 0304U, 0305U. Added codes CAT III: 0672T, 0673T, 0674T, 0675T, 0676T, 0677T, 0678T, 0679T, 0680T, 0681T, 0682T, 0683T, 0684T, 0685T, 0686T, 0687T, 0688T, 0689T, 0690T, 0691T, 0693T, 0694T, 0695T, 0696T, 0697T, 0698T, 0700T, 0701T, 0702T, 0703T, 0704T, 0705T, 0706T, 0707T, 0708T, 0709T, 0710T, 0711T, 0712T, 0713T. Added the following HCPCS

	Codes: A2001, A2002, A2004, A2005, A2006, A2007, A2008, A2009, A2010, C1832, C1833, G0465, Q4199. Removed codes: 0030U, 0032U, 0033U, 0173U, 0175U, 90677.
04/2022	Coding Update Effective 04/01/2022 (Adaptive Maintenance Cycle): A2003 deleted code never became effective 01/01/2021. (0)097U deleted. Added codes: 0306U, 0307U, 0308U, 0309U, 0310U, 0311U, 0312U, 0313U, 0314U, 0315U, 0316U, 0317U, 0318U, 0319U, 0320U, 0321U, 0322U. A2013, A9291, C9781, K1028, K1029, K1030, K1031, K1032, K1033. Removed code J3490 per Ketamine Medical Policy effective 04/01/2022.
05/2022	Coding Update Effective 05/01/2022 (Investigational Medical Policy Reconciliation): Codes removed: A4641, A4642, A9500, A9502, A9520, A9541, A9568, A9572, A9582 may be eligible for benefit approved by AIM or BCBSVT. Codes removed: J9035, 15788, 15789, 15792, 15793, 17000, 17003, 17004, 30520, 17106, 17107, 17108, 82656, 83630, 90677 effective: 01/01/2022), 97032 may be eligible for services based on current standards of care. Codes removed: G0259, L8603*, L8605*, L8606*, L8684, S8080, 0026U, 0097U, 0107U, 0278T, 15824, 15826, 30130, 30140, 31626, 34701, 34702, 34703, 34704, 34705, 34706, 34707, 34708, 36012, 37241, 38242, 43201, 43210, 43212, 43257, 51715, 64590, 64595, 64632, 64640, 64716, 64722, 64771, 64772, 64910, 64911, 64912, 64913, 76940, 78195, 78800, 78801, 78802, 78804, 82239, 82272, 82274, 82397, 82542, 82652, 82710, 82715, 82725, 83520, 83698, 83986, 84311, 86141, 86304, 87045, 87046, 87075, 87102, 87177, 87209, 87328, 87329, 87336, 89160, 89240, 92229, 93895, 95812, 95813, 95816, 95819, 95921, 95922, 95923, 95924, 96904 codes require prior approval. Removed codes: E0748, E0749, J3490, L8680, L8681, L8682, L8683, L8685, L8686, L8687, L8688, L8689, Q4168, Q4185, Q4189, Q4192, S3852, 0029U, 0156U, 0173U, 0175U, 0278U, 0394T, 15780, 15781, 15782, 15783, 20974, 20975, 61885, 61886, 64553, 64568, 64569, 64570, 67900, 75571, 81226, 81291, 81313, 81400, 81401, 81403, 81406, 81407, 81415, 81416, 81417, 81439, 81490, 81493, 81500, 81503, 81504, 81535, 81536, 81538, 81540, 81595, 95980, 95981, 95982 codes always required prior approval. Changed the following codes to be investigational for all diagnoses: A9584, E0740, E0761, E0769, G0166, G0295, G0329, G9147, S3722, 0003U, 0101T, 0102T, 0207T, 0278T, 0330T, 0332T, 0338T, 0339T, 0397T, 0421T, 0424T, 0425T, 0426T, 0441T, 0563T, 28890, 33548, 43206, 43252, 43284, 43285, 43647, 43648, 43881, 43882, 46707, 47371, 47381, 47383, 62263, 62264, 64505, 77085, 77086, 82523, 83006, 83695, 84080, 85384, 86352, 88375, 95957, 97610, 98922. Added new codes: C1825, C9359, C9362, E0746, G9143, S8130, S8131, 0651T, 64575 investigational for all diagnoses. Removed codes: G0281, G0282, V5095, 90876, 97014 codes are considered non-covered. Removed code S2080 code considered not medically necessary. Removed codes 31627 & 57465 not medically necessary per payment policy CPP_04. Added codes to as investigation but have been investigational per applicable medical policy: E0762, E0764, M0076, P9020, S8040, 0232T, 0355T, 41512, 64585, 83937, 91111, 92548, 92145, 92572, 92576, 93701, 95803, 96000, 96001, 96002, 96003, 96004, 97799. Codes deleted: A9599, C9750, 0355T, 0399T, 0406T, 0407T, 30660, 30661, 61632, 98922.
06/2022	Removed codes 0116U & 0117U Effective: 06/01/2022 Added code P2031 Effective: 06/01/2022, Added COVID-19 Monoclonal Antibodies & Administration codes: M0240, M0241, M0243, M0244, M0245, M0246, Q0240, Q0243, Q0244, Q0245

	Effective:01/24/2022. Added COVID-19 Monoclonal Antibodies & Administration codes: M0247, M0248, Q0247 Effective: 04/05/2022.
06/2022	Coding Update Effective 07/01/2022 (Adaptive Maintenance Cycle): Revised code descriptor 0229U. Removed code 83880 off- cycle map as medically necessary. Removed codes 0648T & 0649T from NIV to requiring PA add to PA CAT Code 'MQM' per medical policy changes to be reviewed by AIM 07/01/2022. Removed code 42975, 87426 & C9776 - medically necessary. Removed codes 90626 & 90627 FDA approved covered travel. Removed code 90759 FDA approved - preventive grid. Added codes: 90584, 0714T, 0715T, 0716T, 0717T, 0718T, 0719T, 0720T, 0721T, 0722T, 0723T, 0724T, 0725T, 0726T, 0727T, 0728T, 0729T, 0730T, 0731T, 0732T, 0733T, 0734T, 0735T, 0736T, 0737T, 0323U, 0324U, 0325U, 0328U, 0329U, 0330U, 0331U A9601, Q4259, Q4260, Q4261. Re-sequenced code 0330T.
09/2022	Coding Update Effective 10/01/2022 (Adaptive Maintenance Cycle): Added Codes Q1005, S0596, V2787, V2788, added to the Investigational policy the codes are considered investigational per the Vision Corporate Medical Policy. Removed codes 95976, 95977 & 58674 the codes will require prior approval. Removed code 84181 as investigational. Added the following PLA codes: 0332U, 0333U, 0334U, 0335U, 0336U, 0337U, 0338U, 0339U, 0340U, 0341U, 0342U, 0343U, 0344U, 0345U, 0346U, 0347U, 0348U, 0349U, 0350U, 0351U, 0352U as investigational. Added codes: A2014, A2015, A2016, A2017, A2018, A4596, C1834.
11/2022	Effective 11/01/2022: Removed codes: 0037U & 0129U from investigational to requiring prior approval. Removed codes 85384 & 85385 from investigational to medically necessary. Removed codes 0224U & 0225U from investigational to eligible at zero-cost share COVID-19.
12/2022	Effective 01/01/2023 (Adaptive Cycle Maintenance): Deleted Codes: 0312T, 0313T, 0314T, 0315T, 0316T, 0317T, 0514T, 0702T, 0703T. C1841, G2170, G2171. Revised Codes: 0733T, 0734T. Added codes as Investigational: 22860, 30469, 36836, 36837, 43290, 43291, 77089, 77090, 77091, 77092, 81418, 81449, 81451, 81456, 90678, 98978, 0738T, 0739T, 0740T, 0741T, 0742T, 0743T, 0744T, 0745T, 0746T, 0747T, 0748T, 0749T, 0750T, 0751T, 0752T, 0753T, 0754T, 0755T, 0756T, 0757T, 0758T, 0759T, 0760T, 0761T, 0762T, 0763T, 0764T, 0765T, 0766T, 0767T, 0768T, 0769T, 0770T, 0771T, 0772T, 0773T, 0774T, 0775T, 0776T, 0777T, 0778T, 0779T, 0780T, 0781T, 0782T, 0783T, 0355U, 0356U, 0357U, 0358U, 0359U, 0360U, 0361U, 0362U, 0363U, C1747, C1826, C1827, C7501, C7502, Q4262, Q4263, Q4264. Removed code as Investigational: 0421T.
01/2023	Policy reviewed removed codes 0202U & 0223U from investigational to eligible at zero cost share COVID-19 effective 11/01/2022.
02/2023	Policy reviewed removed code 81518 from investigational to requiring prior approval effective 03/01/2023.
03/2023	Effective 04/01/2023 (Adaptive Maintenance Cycle): C1834, 0324U, 0325U codes deleted. Code 0095U descriptor revised. Removed codes 0449T, 0450T, 90758 from investigational to medically necessary. Added codes: 0364U, 0365U, 0366U, 0367U, 0369U, 0370U, 0371U, 0372U, 0374U, 0375U, 0376U, 0377U, 0378U, 0379U, 0380U, 0384U, 0385U, 0386U, A2019, A2020, A2021, A4341, A4342, A4560, A6590, A6591, A7049, E0677, E0711, E1905, L8678, Q4265, Q4266, Q4267, Q4268, Q4269, Q4270, Q4271 as investigational to the coding table
03/2023	Effective 06/01/2023 Medical Policy Review- Added codes: E1806,

	E1811, E1816, E1818, E1821, E1831, E1841
06/2023	Effective 07/01/2023 (Adaptive Maintenance Cycle): Removed codes: 83721, 90671. Deleted Code: 0053U. Added Codes: 0387U, 0389U, 0390U, 0391U, 0392U, 0393U, 0394U, 0395U, 0398U, 0399U, 0400U, 0401U, 0791T, 0792T, 0793T, 0794T, 0795T, 0796T, 0797T, 0798T, 0799T, 0800T, 0801T, 0802T, 0803T, 0804T, 0805T, 0806T, 0807T, 0808T, 0809T, C9150, C9784, C9785, C9786, C9787, Q4272, Q4273, Q4274, Q4275, Q4276, Q4277, Q4278, Q4280, Q4281, Q4282, Q4283, Q4284. Added Codes (COVID-19): Refer to dates in table: 91300, 91301, 91303, 91305, 91306, 91307, 91308, 91309, 91311, 0001A, 0002A, 0003A, 0004A, 0011A, 0012A, 0013A, 0031A, 0034A, 0051A, 0052A, 0053A, 0054A, 0064A, 0071A, 0072A, 0073A, 0074A, 0081A, 0082A, 0083A, 0091A, 0092A, 0093A, 0094A, 0111A, 0112A, M0220, M0221, M0222, M0223, M0240, M0241, M0243, M0244, M0245, M0246, M0247, M0248, Q0220, Q0221, Q0222, Q0240, Q0243, Q0244, Q0245, Q0247.
09/2023	Effective 10/01/2023 (Adaptive Maintenance Cycle): Revised: 0362U, 0389U, 0401U, K1004, K1028. Deleted: 0357U, 0386U. Removed: 90678 code medically necessary. Added: 0019M, 0071T, 0072T, 0403U, 0404U, 0405U, 0406U, 0407U, 0408U, 0410U, 0411U, 0412U, 0413U, 0414U, 0415U, 0416U, 0417U, 0418U, 0419U, A2022, A2023, A2024, A2025, A9268, A9269, A9292, A9573, A9603, A9697, C9788, C9790, C9791, C9792, E0490, E0491, K1036, Q4285, Q4286.
10/2023	Effective 12/01/2023: Codes 36473 & 36474 added as Investigational.
12/2023	Adaptive Maintenance Effective 01/01/2024: Removed code 0404T from investigational to requiring prior approval.  Added codes: 22836,, 22837, 22838, 31242, 31243, 33276, 33277, 33278, 33279, 33280, 33281, 33287, 33288, 52284, 90589, 90683, 92972, 93150, 93151, 93152, 93153, A6566, A6567,A7023, A9609,C1600, E0492, E0493, E0530, E0732, E0733, E0734, E2001, Q4279, Q4287, Q4288, Q4289, Q4290, Q4291, Q4292, Q4293, Q4294, Q4295, Q4296, Q4297, Q4298, Q4299, Q4300, Q4301, Q4302, Q4303, Q4304, 0420U, 0421U, 0422U, 0423U, 0424U, 0427U, 0429U, 0430U, 0431U, 0432U, 0433U, 0434U, 0435U, 0436U, 0437U, 0438U,0790T, 0811T, 0812T, 0813T, 0814T, 0815T, 0820T, 0821T, 0827T, 0828T, 0829T, 0830T, 0831T, 0832T, 0833T, 0834T, 0835T, 0836T, 0837T, 0838T, 0839T, 0840T, 0841T, 0842T, 0843T, 0844T, 0845T, 0846T, 0847T, 0848T, 0849T, 0850T, 0851T, 0858T.  0852T, 0853T, 0854T, 0855T, 0856T, 0857T, 0859T, 0860T, 0861T, 0862T, 0863T, 0864T, 0865T, 0866T  Revised Codes: 81451, 81456, 0517T, 0518T, 0519T, 0520T, 0587T, 0588T, 0589T, 0590T, 0640T, 0656T, 0657T, 0766T, 0767T. 0095U, 0351U, 0356U,  Deleted Codes: 0404T, 0424T, 0425T, 0426T, 0427T, 0428T, 0429T, 0430T, 0431T, 0432T, 0433T, 0434T, 0435T, 0436T, 0508T, 0533T, 0534T, 0533T, 0535T, 0536T, 0715T, 0768T, 0769T, 0775T, 0809T, 0014M, K1001, K1002, C9771, C9788, K1006, K1016, K1017, K1018, K1019, K1020, K1023, K1024,

	<p>K1025, K1026, K1028, K1029, K1031, K1032, K1033,</p> <p>Removed code C2596 from investigational to medically necessary.</p>
04/2024	<p>Adaptive Maintenance Effective 04/01/2024: Added Codes: 27278, 0439U, 0440U, 0441U, 0442U, 0443U, 0444U, 0445U, 0446U, 0447U, 0449U, A2026, A4438, A4593, A4594, E0468, E0736, E0738, E0739, K1037, Q4305, Q4306, Q4307, Q4308, Q4309, Q4310, S4988, S9002 as investigational to coding table.</p> <p>Added Codes: C9796 &amp; C9797 retroactive to 01/01/2024 Adaptive Maintenance Cycle as investigational to coding table.</p> <p>Removed Code: 0242U from investigational from coding table now requires PA.</p> <p>Deleted Code: 0416U from coding table.</p> <p>Revised Code: E2001 in coding table.</p>
07/2024	<p>Adaptive Maintenance Effective 07/01/2024: Added Codes: 0020M, 0867T, 0868T, 0870T, 0871T, 0872T, 0873T, 0874T, 0875T, 0876T, 0877T, 0878T, 0879T, 0880T, 0881T, 0882T, 0883T, 0884T, 0885T, 0886T, 0887T, 0888T, 0889T, 0890T, 0891T, 0892T, 0893T, 0894T, 0895T, 0896T, 0897T, 0898T, 0899T, 0900T, 0450U, 0451U, 0452U, 0453U, 0456U, 0457U, 0458U, 0460U, 0461U, 0462U, 0463U, 0464U, 0465U, 0466U, 0467U, 0468U, 0469U, 0470U, 0472U, 0474U, 0475U, 90637, 90638, Q4311, Q4312, Q4313, Q4314, Q4315, Q4316, Q4317, Q4318, Q4319, Q4320, Q4321, Q4322, Q4323, Q4324, Q4325, Q4326, Q4327, Q4328, Q4329, Q4330, Q4331, Q4332, Q4333 as investigational to coding table.</p> <p>Removed Codes: 0279U, 0280U, 0281U, 0282U, 0283U, 0284U, C9359, 90589, 90683 from coding table.</p> <p>Deleted Codes: 0204U, C9787, C9790, Q4277 from coding table.</p> <p>Revised Codes: 0741T in coding table.</p>
07/2024	<p>Removed CPT® code 33274 from investigational coding table, code will require prior approval.</p>

### Eligible Providers

Qualified healthcare professionals practicing within the scope of their license(s).

### Approved by BCBSVT Medical Directors

Tom Weigel, MD, MBA  
Vice President and Chief Medical Officer

Tammaji P. Kulkarni, MD  
Senior Medical Director

**Attachment I**

<b>CPT®/HCPCS Code</b>	<b>CPT®/HCPCS Code Description</b>	<b>Instructions</b>
<b>A2001</b>	InnovaMatrix AC, per sq cm	Investigational
<b>A2002</b>	Mirragen Advanced Wound Matrix, per sq cm	Investigational
<b>A2004</b>	XCelliStem, per sq cm	Investigational
<b>A2005</b>	Microlyte Matrix, per sq cm	Investigational
<b>A2006</b>	NovoSorb SynPath dermal matrix, per sq cm	Investigational
<b>A2007</b>	Restrata, per sq cm	Investigational
<b>A2008</b>	TheraGenesis, per sq cm	Investigational
<b>A2009</b>	Symphony, per sq cm	Investigational
<b>A2010</b>	Apis, per sq cm	Investigational
<b>A2013</b>	Innovamatrix FS, per sq cm	Investigational
<b>A2014</b>	Omeza collagen matrix, per 100 mg	Investigational
<b>A2015</b>	Phoenix wound matrix, per square centimeter	Investigational
<b>A2016</b>	Permeaderm b, per square centimeter	Investigational
<b>A2017</b>	Permeaderm glove, each	Investigational
<b>A2018</b>	Permeaderm c, per square centimeter	Investigational
<b>A2019</b>	Kerecis omega3 marigen shield, per square centimeter	Investigational
<b>A2020</b>	Ac5 advanced wound system (ac5)	Investigational
<b>A2021</b>	Neomatrix, per square centimeter	Investigational
<b>A2022</b>	Innovaburn or innovamatrix xl, per square centimeter	Investigational
<b>A2023</b>	Innovamatrix pd, 1 mg	Investigational
<b>A2024</b>	Resolve matrix, per square centimeter	Investigational
<b>A2025</b>	Miro3d, per cubic centimeter	Investigational
<b>A2026</b>	Restrata minimatrix, 5 mg	Investigational
<b>A4341</b>	Indwelling intraurethral drainage device with valve, patient inserted, replacement only, each	Investigational



<b>A4342</b>	Accessories for patient inserted indwelling intraurethral drainage device with valve, replacement only, each	Investigational
<b>A4438</b>	Adhesive clip applied to the skin to secure external electrical nerve stimulator controller, each	Investigational
<b>A4560</b>	Neuromuscular electrical stimulator (nmes), disposable, replacement only	Investigational
<b>A4563</b>	Rectal control system for vaginal insertion, for long term use, includes pump and all supplies and accessories, any type each	Investigational
<b>A4575</b>	Topical hyperbaric oxygen chamber, disposable	Investigational
<b>A4593</b>	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime	Investigational
<b>A4594</b>	Neuromodulation stimulator system, adjunct to rehabilitation therapy regime, mouthpiece each	Investigational
<b>A4596</b>	Cranial electrotherapy stimulation (ces) system supplies and accessories, per month	Investigational
<b>A6566</b>	Gradient compression garment, neck/head, each	Investigational
<b>A6567</b>	Gradient compression garment, neck/head, custom, each	Investigational
<b>A6590</b>	External urinary catheters; disposable, with wicking material, for use with suction pump, per month	Investigational
<b>A6591</b>	External urinary catheter; non-disposable, for use with suction pump, per month	Investigational
<b>A7023</b>	Mechanical allergen particle barrier/inhalation filter, cream, nasal, topical	Investigational
<b>A7049</b>	Expiratory positive airway pressure intranasal resistance valve	Investigational
<b>A9268</b>	Programmer for transient, orally ingested capsule	Investigational
<b>A9269</b>	Programable, transient, orally ingested capsule, for use with external programmer, per month	Investigational

<b>A9291</b>	Prescription digital behavioral therapy, FDA-cleared, per course of treatment	Investigational
<b>A9292</b>	Prescription digital visual therapy, software-only, fda cleared, per course of treatment	Investigational
<b>A9507</b>	Indium In-111 capromab pentetide, diagnostic, per study dose, up to 10 millicuries	Investigational
<b>A9573</b>	Injection, gadopiclenol, 1 ml	Investigational
<b>A9584</b>	Iodine I-123 ioflupane, diagnostic, per study dose, up to 5 mCi	Investigational
<b>A9586</b>	Florbetapir F18, diagnostic, per study dose, up to 10 mCi	Investigational
<b>A9593</b>	Gallium Ga-68 PSMA-11, diagnostic, (UCSF), 1 mCi	Investigational
<b>A9594</b>	Gallium Ga-68 PSMA-11, diagnostic, (UCLA), 1 mCi	Investigational
<b>A9601</b>	Flortaucipir f 18 injection, diagnostic, 1 millicurie	Investigational
<b>A9603</b>	Injection, pafolacianine, 0.1 mg	Investigational
<b>A9609</b>	Gradient compression bandaging supply, not otherwise specified	Investigational
<b>A9697</b>	Injection, carboxydextran-coated superparamagnetic iron oxide, per study dose	Investigational
<b>C1600</b>	Catheter, transluminal intravascular lesion preparation device, bladed, sheathed (insertable)	Investigational
<b>C1734</b>	Orthopedic/device/drug matrix for opposing bone-to-bone or soft tissue-to bone (implantable)	Investigational
<b>C1747</b>	Endoscope, single-use (i.e. disposable), urinary tract, imaging/illumination device (insertable)	Investigational
<b>C1761</b>	Catheter, transluminal intravascular lithotripsy, coronary	Investigational
<b>C1821</b>	Interspinous process distraction device (implantable)	Investigational
<b>C1823</b>	Generator, neurostimulator (implantable), nonrechargeable, with transvenous sensing and stimulation leads	Investigational

<b>C1825</b>	Generator, neurostimulator (implantable), nonrechargeable with carotid sinus baroreceptor stimulation lead(s)	Investigational
<b>C1826</b>	Generator, neurostimulator (implantable), includes closed feedback loop leads and all implantable components, with rechargeable battery and charging system	Investigational
<b>C1827</b>	Generator, neurostimulator (implantable), non-rechargeable, with implantable stimulation lead and external paired stimulation controller	Investigational
<b>C1831</b>	Personalized, anterior and lateral interbody cage (implantable)	Investigational
<b>C1832</b>	Autograft suspension, including cell processing and application, and all system components	Investigational
<b>C1833</b>	Monitor, cardiac, including intracardiac lead and all system components (implantable)	Investigational
<b>C2614</b>	Probe, percutaneous lumbar discectomy	Investigational
<b>C7501</b>	Percutaneous breast biopsies using stereotactic guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral and bilateral (for single lesion biopsy, use appropriate code)	Investigational
<b>C7502</b>	Percutaneous breast biopsies using magnetic resonance guidance, with placement of breast localization device(s) (eg, clip, metallic pellet), when performed, and imaging of the biopsy specimen, when performed, all lesions unilateral or bilateral (for single lesion biopsy, use appropriate code)	Investigational

<b>C8937</b>	Computer-aided detection, including computer algorithm analysis of breast MRI image data for lesion detection/characterization, pharmacokinetic analysis, with further physician review for interpretation (list separately in addition to code for primary procedure)	Investigational
<b>C9150</b>	Xenon xe-129 hyperpolarized gas, diagnostic, per study dose	Investigational
<b>C9354</b>	Acellular pericardial tissue matrix of nonhuman origin (Veritas), per sq cm	Investigational
<b>C9356</b>	Tendon, porous matrix of cross-linked collagen and glycosaminoglycan matrix (TenoGlide Tendon Protector Sheet), per sq cm	Investigational
<b>C9358</b>	Dermal substitute, native, nondenatured collagen, fetal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
<b>C9360</b>	Dermal substitute, native, nondenatured collagen, neonatal bovine origin (SurgiMend Collagen Matrix), per 0.5 sq cm	Investigational
<b>C9362</b>	Porous purified collagen matrix bone void filler (Integra Mozaik Osteoconductive Scaffold Strip), per 0.5 cc	Investigational
<b>C9363</b>	Skin substitute (Integra Meshed Bilayer Wound Matrix), per sq cm	Investigational
<b>C9364</b>	Porcine implant, Permacol, per sq cm	Investigational

<b>C9751</b>	Bronchoscopy, rigid or flexible, transbronchial ablation of lesion(s) by microwave energy, including fluoroscopic guidance, when performed, with computed tomography acquisition(s) and 3D rendering, computer-assisted, image-guided navigation, and endobronchial ultrasound (EBUS) guided transtracheal and/or transbronchial sampling (e.g., aspiration[s]/biopsy[ies]) and all mediastinal and/or hilar lymph node stations or structures and therapeutic intervention(s)	Investigational
<b>C9758</b>	Blind procedure for NYHA Class III/IV heart failure; transcatheter implantation of interatrial shunt including right heart catheterization, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational
<b>C9759</b>	Transcatheter intraoperative blood vessel microinfusion(s) (e.g., intraluminal, vascular wall and/or perivascular) therapy, any vessel, including radiological supervision and interpretation, when performed	Investigational

<b>C9760</b>	Nonrandomized, nonblinded procedure for NYHA Class II, III, IV heart failure; transcatheter implantation of interatrial shunt, including right and left heart catheterization, transeptal puncture, transesophageal echocardiography (TEE)/intracardiac echocardiography (ICE), and all imaging with or without guidance (e.g., ultrasound, fluoroscopy), performed in an approved investigational device exemption (IDE) study	Investigational
<b>C9762</b>	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with strain imaging	Investigational
<b>C9763</b>	Cardiac magnetic resonance imaging for morphology and function, quantification of segmental dysfunction; with stress imaging	Investigational
<b>C9764</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9765</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9766</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational

<b>C9767</b>	Revascularization, endovascular, open or percutaneous, lower extremity artery(ies), except tibial/peroneal; with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9772</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies), with intravascular lithotripsy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9773</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy, and transluminal stent placement(s), includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9774</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9775</b>	Revascularization, endovascular, open or percutaneous, tibial/peroneal artery(ies); with intravascular lithotripsy and transluminal stent placement(s), and atherectomy, includes angioplasty within the same vessel(s), when performed	Investigational
<b>C9777</b>	Esophageal mucosal integrity testing by electrical impedance, transoral, includes esophagoscopy or esophagogastroduodenoscopy	Investigational
<b>C9780</b>	Insertion of central venous catheter through central venous occlusion via inferior and superior approaches (e.g., inside-out technique), including imaging guidance	Investigational

<b>C9781</b>	Arthroscopy, shoulder, surgical; with implantation of subacromial spacer (e.g., balloon), includes debridement (e.g., limited or extensive), subacromial decompression, acromioplasty, and biceps tenodesis when performed	Investigational
<b>C9784</b>	Gastric restrictive procedure, endoscopic sleeve gastroplasty, with esophagogastroduodenoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational
<b>C9785</b>	Endoscopic outlet reduction, gastric pouch application, with endoscopy and intraluminal tube insertion, if performed, including all system and tissue anchoring components	Investigational
<b>C9786</b>	Echocardiography image post processing for computer aided detection of heart failure with preserved ejection fraction, including interpretation and report	Investigational
<b>C9791</b>	Magnetic resonance imaging with inhaled hyperpolarized xenon-129 contrast agent, chest, including preparation and administration of agent	Investigational
<b>C9792</b>	Blinded or nonblinded procedure for symptomatic new york heart association (nyha) class ii, iii, iva heart failure; transcatheter implantation of left atrial to coronary sinus shunt using jugular vein access, including all imaging necessary to intra procedurally map the coronary sinus for optimal shunt placement (e.g., tee or ice ultrasound, fluoroscopy), performed under general anesthesia in an approved investigational device exemption (ide) study)	Investigational



<b>C9796</b>	Repair of enterocutaneous fistula small intestine or colon (excluding anorectal fistula) with plug (e.g., porcine small intestine submucosa [sis])	Investigational
<b>C9797</b>	Vascular embolization or occlusion procedure with use of a pressure-generating catheter (e.g., one-way valve, intermittently occluding), inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; for tumors, organ ischemia, or infarction	Investigational
<b>E0218</b>	Fluid circulating cold pad with pump, any type	Investigational
<b>E0236</b>	Pump for water circulating pad	Investigational
<b>E0468</b>	Home ventilator, dual-function respiratory device, also performs additional function of cough stimulation, includes all accessories, components and supplies for all functions	Investigational
<b>E0490</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by hardware remote	Investigational
<b>E0491</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by hardware remote, 90-day supply	Investigational
<b>E0492</b>	Power source and control electronics unit for oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, controlled by phone application	Investigational

<b>E0493</b>	Oral device/appliance for neuromuscular electrical stimulation of the tongue muscle, used in conjunction with the power source and control electronics unit, controlled by phone application, 90-day supply	Investigational
<b>E0530</b>	Electronic positional obstructive sleep apnea treatment, with sensor, includes all components and accessories, any type	Investigational
<b>E0677</b>	Non-pneumatic sequential compression garment, trunk	Investigational
<b>E0711</b>	Upper extremity medical tubing/lines enclosure or covering device, restricts elbow range of motion	Investigational
<b>E0732</b>	Cranial electrotherapy stimulation (ces) system, any type	Investigational
<b>E0733</b>	Transcutaneous electrical nerve stimulator for electrical stimulation of the trigeminal nerve	Investigational
<b>E0734</b>	External upper limb tremor stimulator of the peripheral nerves of the wrist	Investigational
<b>E0736</b>	Transcutaneous tibial nerve stimulator	Investigational
<b>E0738</b>	Upper extremity rehabilitation system providing active assistance to facilitate muscle re-education, include microprocessor, all components and accessories	Investigational
<b>E0739</b>	Rehab system with interactive interface providing active assistance in rehabilitation therapy, includes all components and accessories, motors, microprocessors, sensors	Investigational
<b>E0740</b>	Nonimplanted pelvic floor electrical stimulator, complete system	Investigational
<b>E0746</b>	Electromyography (EMG), biofeedback device	Investigational

<b>E0761</b>	Nonthermal pulsed high frequency radiowaves, high peak power electromagnetic energy treatment device	Investigational
<b>E0762</b>	Transcutaneous electrical joint stimulation device system, includes all accessories	Investigational
<b>E0764</b>	Functional neuromuscular stimulation, transcutaneous stimulation of sequential muscle groups of ambulation with computer control, used for walking by spinal cord injured, entire system, after completion of training program	Investigational
<b>E0769</b>	Electrical stimulation or electromagnetic wound treatment device, not otherwise classified	Investigational
<b>E0770</b>	Functional electrical stimulator, transcutaneous stimulation of nerve and/or muscle groups, any type, complete system, not otherwise specified	Investigational
<b>E1700</b>	Jaw motion rehabilitation system	Investigational
<b>E1701</b>	Replacement cushions for jaw motion rehabilitation system, package of 6	Investigational
<b>E1702</b>	Replacement measuring scales for jaw motion rehabilitation system, package of 200	Investigational
<b>E1801</b>	Static progressive stretch elbow device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1806</b>	Static progressive stretch wrist device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1811</b>	Static progressive stretch knee device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1816</b>	Static progressive stretch ankle device, flexion and/or extension, with or without range of motion adjustment, includes all components and accessories	Investigational

<b>E1818</b>	Static progressive stretch forearm pronation/supination device, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1821</b>	Replacement soft interface material/cuffs for bi-directional static progressive stretch device	Investigational
<b>E1831</b>	Static progressive stretch toe device, extension and/or flexion, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1841</b>	Static progressive stretch shoulder device, with or without range of motion adjustment, includes all components and accessories	Investigational
<b>E1905</b>	Virtual reality cognitive behavioral therapy device (cbt), including pre-programmed therapy software	Investigational
<b>E2001</b>	Suction pump, home model, portable or stationary, electric, any type, for use with external urine/or fecal management system	Investigational
<b>G0166</b>	External counterpulsation, per treatment session	Investigational
<b>G0255</b>	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve	Investigational
<b>G0276</b>	Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (PILD) or placebo-control, performed in an approved coverage with evidence development (CED) clinical trial	Investigational
<b>G0295</b>	Electromagnetic therapy, to one or more areas, for wound care other than described in G0329 or for other uses	Investigational
<b>G0327</b>	Colorectal cancer screening; blood-based biomarker	Investigational

<b>G0329</b>	Electromagnetic therapy, to one or more areas for chronic Stage III and Stage IV pressure ulcers, arterial ulcers, diabetic ulcers and venous stasis ulcers not demonstrating measurable signs of healing after 30 days of conventional care as part of a therapy plan of care	Investigational
<b>G0465</b>	Autologous platelet rich plasma (PRP) for diabetic chronic wounds/ulcers, using an FDA-cleared device (includes administration, dressings, phlebotomy, centrifugation, and all other preparatory procedures, per treatment)	Investigational
<b>G2000</b>	Blinded administration of convulsive therapy procedure, either electroconvulsive therapy (ECT, current covered gold standard) or magnetic seizure therapy (MST, noncovered experimental therapy), performed in an approved IDE-based clinical trial, per treatment session	Investigational
<b>G9143</b>	Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s)	Investigational
<b>G9147</b>	Outpatient Intravenous Insulin Treatment (OIVIT) either pulsatile or continuous, by any means, guided by the results of measurements for: respiratory quotient; and/or, urine urea nitrogen (UUN); and/or, arterial, venous or capillary glucose; and/or potassium concentration	Investigational
<b>K1004</b>	Low frequency ultrasonic diathermy treatment device for home use	Investigational

<b>K1007</b>	Bilateral hip, knee, ankle, foot (HKAFO) device, powered, includes pelvic component, single or double upright(s), knee joints any type, with or without ankle joints any type, includes all components and accessories, motors, microprocessors, sensors	Investigational
<b>K1030</b>	External recharging system for battery (internal) for use with implanted cardiac contractility modulation generator, replacement only	Investigational
<b>K1036</b>	Supplies and accessories (e.g., transducer) for low frequency ultrasonic diathermy treatment device, per month	Investigational
<b>K1037</b>	Docking station for use with oral device/appliance used to reduce upper airway collapsibility	Investigational
<b>L8608</b>	Miscellaneous external component, supply or accessory for use with the Argus II Retinal Prosthesis System	Investigational
<b>L8678</b>	Electrical stimulator supplies (external) for use with implantable neurostimulator, per month	Investigational
<b>M0076</b>	Prolotherapy	Investigational
<b>M0220</b>	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring	Investigational COVID-19 Effective:(01/26/2023)

<b>M0221</b>	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(01/26/2023)
<b>M0222</b>	Intravenous injection, bebtelovimab, includes injection and post administration monitoring	Investigational COVID-19 Effective:(11/30/2022)
<b>M0223</b>	Intravenous injection, bebtelovimab, includes injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(11/30/2022)
<b>M0240</b>	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring, subsequent repeat doses	Investigational COVID-19 Effective:(01/24/2022)

<b>M0241</b>	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring in the home or residence. This includes a beneficiary's home that has been made provider-based to the hospital during the covid-19 public health emergency, subsequent repeat doses	Investigational COVID-19 Effective:(01/24/2022)
<b>M0243</b>	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection, and post administration monitoring	Investigational COVID-19 Effective:(01/24/2022)
<b>M0244</b>	Intravenous infusion or subcutaneous injection, casirivimab and imdevimab, includes infusion or injection and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(01/24/2022)
<b>M0245</b>	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring	Investigational COVID-19 Effective:(01/24/2022)
<b>M0246</b>	Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(01/24/2022)
<b>M0247</b>	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring	Investigational COVID-19 Effective:(04/05/2022)



<b>M0248</b>	Intravenous infusion, sotrovimab, includes infusion and post administration monitoring in the home or residence; this includes a beneficiary's home that has been made provider-based to the hospital during the COVID-19 public health emergency	Investigational COVID-19 Effective:(04/05/2022)
<b>P2031</b>	Hair analysis (excluding arsenic)	Investigational
<b>P9020</b>	Platelet rich plasma, each unit	Investigational
<b>Q0220</b>	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 300 mg	Investigational COVID-19 Effective:(01/26/2023)
<b>Q0221</b>	Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known SARS-CoV-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available COVID-19 vaccine is not recommended due to a history of severe adverse reaction to a COVID-19 vaccine(s) and/or COVID-19 vaccine component(s), 600 mg	Investigational COVID-19 Effective:(01/26/2023)
<b>Q0222</b>	Injection, bebtelovimab, 175 mg	Investigational COVID-19 Effective:(11/30/2022)
<b>Q0240</b>	Injection, casirivimab and imdevimab, 600 mg	Investigational COVID-19 Effective:(01/24/2022)
<b>Q0243</b>	Injection, casirivimab and imdevimab, 2400 mg	Investigational COVID-19 Effective:(01/24/2022)

Q0244	Injection, casirivimab and imdevimab, 1200 mg	Investigational COVID-19 Effective:(01/24/2022)
Q0245	Injection, bamlanivimab and etesevimab, 2100 mg	Investigational COVID-19 Effective:(01/24/2022)
Q0247	Injection, sotrovimab, 500 mg	Investigational COVID-19 Effective:(04/05/2022)
Q1005	New technology, intraocular lens, category 5 as defined in Federal Register notice	Investigational
Q4103	Oasis burn matrix, per sq cm	Investigational
Q4104	Integra bilayer matrix wound dressing (BMWd), per sq cm	Investigational
Q4110	PriMatrix, per sq cm	Investigational
Q4111	GammaGraft, per sq cm	Investigational
Q4112	Cymetra, injectable, 1 cc	Investigational
Q4113	GRAFTJACKET XPRESS, injectable, 1 cc	Investigational
Q4115	AlloSkin, per sq cm	Investigational
Q4117	HYALOMATRIX, per sq cm	Investigational
Q4118	MatriStem micromatrix, 1 mg	Investigational
Q4121	TheraSkin, per sq cm	Investigational
Q4123	AlloSkin RT, per sq cm	Investigational
Q4124	OASIS ultra tri-layer wound matrix, per sq cm	Investigational
Q4125	ArthroFlex, per sq cm	Investigational
Q4126	MemoDerm, DermaSpan, TranZgraft or InteguPly, per sq cm	Investigational
Q4127	Talymed, per sq cm	Investigational
Q4130	Strattice TM, per sq cm	Investigational
Q4134	HMatrix, per sq cm	Investigational
Q4135	Mediskin, per sq cm	Investigational
Q4136	E-Z Derm, per sq cm	Investigational
Q4141	AlloSkin AC, per sq cm	Investigational
Q4142	XCM biologic tissue matrix, per sq cm	Investigational
Q4143	Repriza, per sq cm	Investigational
Q4146	Tensix, per sq cm	Investigational
Q4147	Architect, Architect PX, or Architect FX, extracellular matrix, per sq cm	Investigational
Q4149	Excellagen, 0.1 cc	Investigational
Q4152	DermaPure, per sq cm	Investigational
Q4158	Kerecis Omega3, per sq cm	Investigational
Q4161	bio-ConneKt wound matrix, per sq cm	Investigational
Q4164	Helicoll, per sq cm	Investigational

Q4165	Keramatrix or Kerasorb, per sq cm	Investigational
Q4166	Cytal, per sq cm	Investigational
Q4167	Truskin, per sq cm	Investigational
Q4179	FlowerDerm, per sq cm	Investigational
Q4182	Transcyte, per sq cm	Investigational
Q4193	Coll-e-Derm, per sq cm	Investigational
Q4196	PuraPly AM, per sq cm	Investigational
Q4199	Cygnus matrix, per sq cm	Investigational
Q4200	SkinTE, per sq cm	Investigational
Q4202	Keroxx (2.5 g/cc), 1 cc	Investigational
Q4203	Derma-Gide, per sq cm	Investigational
Q4222	ProgenaMatrix, per sq cm	Investigational
Q4251	Vim, per sq cm	Investigational
Q4252	Vendaje, per sq cm	Investigational
Q4253	Zenith Amniotic Membrane, per sq cm	Investigational
Q4259	Celera dual layer or celera dual membrane, per square centimeter	Investigational
Q4260	Signature apatch, per square centimeter	Investigational
Q4261	Tag, per square centimeter	Investigational
Q4262	Dual layer impax membrane, per square centimeter	Investigational
Q4263	Surgraft tl, per square centimeter	Investigational
Q4264	Cocoon membrane, per square centimeter	Investigational
Q4265	Neostim tl, per square centimeter	Investigational
Q4266	Neostim membrane, per square centimeter	Investigational
Q4267	Neostim dl, per square centimeter	Investigational
Q4268	Surgraft ft, per square centimeter	Investigational
Q4269	Surgraft xt, per square centimeter	Investigational
Q4270	Complete sl, per square centimeter	Investigational
Q4271	Complete ft, per square centimeter	Investigational
Q4272	Esano a, per square centimeter	Investigational
Q4273	Esano aaa, per square centimeter	Investigational
Q4274	Esano ac, per square centimeter	Investigational
Q4275	Esano aca, per square centimeter	Investigational
Q4276	Orion, per square centimeter	Investigational
Q4278	Epieffect, per square centimeter	Investigational
Q4279	Vendaje ac, per square centimeter	Investigational
Q4280	Xcell amnio matrix, per square centimeter	Investigational

Q4281	Barrera sl or barrera dl, per square centimeter	Investigational
Q4282	Cygnus dual, per square centimeter	Investigational
Q4283	Biovance tri-layer or biovance 3l, per square centimeter	Investigational
Q4284	Dermabind sl, per square centimeter	Investigational
Q4285	Nudyn dl or nudyn dl mesh, per square centimeter	Investigational
Q4286	Nudyn sl or nudyn slw, per square centimeter	Investigational
Q4287	Dermabind dl, per square centimeter	Investigational
Q4288	Dermabind ch, per square centimeter	Investigational
Q4289	Revoshield + amniotic barrier, per square centimeter	Investigational
Q4290	Membrane wrap-hydro, per square centimeter	Investigational
Q4291	Lamellas xt, per square centimeter	Investigational
Q4292	Lamellas, per square centimeter	Investigational
Q4393	Acesso dl, per square centimeter	Investigational
Q4294	Amnio quad-core, per square centimeter	Investigational
Q4295	Amnio tri-core amniotic, per square centimeter	Investigational
Q4296	Rebound matrix, per square centimeter	Investigational
Q4297	Emerge matrix, per square centimeter	Investigational
Q4298	Amniocore pro, per square centimeter	Investigational
Q4299	Amnicore pro+, per square centimeter	Investigational
Q4300	Acesso tl, per square centimeter	Investigational
Q4301	Activate matrix, per square centimeter	Investigational
Q4302	Complete aca, per square centimeter	Investigational
Q4303	Complete aa, per square centimeter	Investigational
Q4304	Grafix plus, per square centimeter	Investigational
Q4305	American amnion ac tri-layer, per square centimeter"	Investigational

Q4306	American amnion ac, per square centimeter	Investigational
Q4307	American amnion, per square centimeter	Investigational
Q4308	Sanopellis, per square centimeter	Investigational
Q4309	Via matrix, per square centimeter	Investigational
Q4310	Procenta, per 100 mg	Investigational
Q4311	<b>Acesso, per square centimeter</b>	Investigational
Q4312	<b>Acesso ac, per square centimeter</b>	Investigational
Q4313	<b>Dermabind fm, per square centimeter</b>	Investigational
Q4314	<b>Reeva ft, per square centimeter</b>	Investigational
Q4315	<b>Regenelink amniotic membrane allograft, per square centimeter</b>	Investigational
Q4316	<b>Amchoplast, per square centimeter</b>	Investigational
Q4317	<b>Vitograft, per square centimeter</b>	Investigational
Q4318	<b>E-graft, per square centimeter</b>	Investigational
Q4319	<b>Sanograft, per square centimeter</b>	Investigational
Q4320	<b>Pellograft, per square centimeter</b>	Investigational
Q4321	<b>Renograft, per square centimeter</b>	Investigational
Q4322	<b>Caregraft, per square centimeter</b>	Investigational
Q4323	<b>Alloply, per square centimeter</b>	Investigational
Q4324	<b>Amniotx, per square centimeter</b>	Investigational
Q4325	<b>Acapatch, per square centimeter</b>	Investigational
Q4326	<b>Woundplus, per square centimeter</b>	Investigational
Q4327	<b>Duoamnion, per square centimeter</b>	Investigational
Q4328	<b>Most, per square centimeter</b>	Investigational
Q4329	<b>Singlay, per square centimeter</b>	Investigational
Q4330	<b>Total, per square centimeter</b>	Investigational

<b>Q4331</b>	<b>Axolotl graft, per square centimeter</b>	Investigational
<b>Q4332</b>	<b>Axolotl dualgraft, per square centimeter</b>	Investigational
<b>Q4333</b>	<b>Ardeograaft, per square centimeter</b>	Investigational
<b>Q9982</b>	Flutemetamol F18, diagnostic, per study dose, up to 5 mCi	Investigational
<b>Q9983</b>	Florbetaben F18, diagnostic, per study dose, up to 8.1 mCi	Investigational
<b>S0596</b>	Phakic intraocular lens for correction of refractive error	Investigational
<b>S1091</b>	Stent, noncoronary, temporary, with delivery system (Propel)	Investigational
<b>S2117</b>	Arthroereisis, subtalar	Investigational
<b>S2230</b>	Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear	Investigational
<b>S2348</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, using radiofrequency energy, single or multiple levels, lumbar	Investigational
<b>S3722</b>	Dose optimization by area under the curve (AUC) analysis, for infusional 5-fluorouracil	Investigational
<b>S4988</b>	Penile contracture device, manual, greater than 3 lbs traction force	Investigational
<b>S8040</b>	Topographic brain mapping	Investigational
<b>S8130</b>	Interferential current stimulator, 2 channel	Investigational
<b>S8131</b>	Interferential current stimulator, 4 channel	Investigational
<b>S8930</b>	Electrical stimulation of auricular acupuncture points; each 15 minutes of personal one-on-one contact with patient	Investigational
<b>S9002</b>	Intra-vaginal motion sensor system, provides biofeedback for pelvic floor muscle rehabilitation device	Investigational
<b>S9090</b>	Vertebral axial decompression, per session	Investigational
<b>V2787</b>	Astigmatism correcting function of intraocular lens	Investigational

<b>V2788</b>	Presbyopia correcting function of intraocular lens	Investigational
<b>V2799</b>	Vision item or service, miscellaneous	Investigational
<b>0001A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0002A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted; second dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0003A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0003U</b>	Oncology (ovarian) biochemical assays of five proteins (apolipoprotein A-1, CA 125 II, follicle stimulating hormone, human epididymis protein 4, transferrin), utilizing serum, algorithm reported as a likelihood score	Investigational
<b>0004A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; booster dose	Investigational COVID-19 Effective:(04/18/2023)

<b>0004M</b>	Scoliosis, DNA analysis of 53 single nucleotide polymorphisms (SNPs), using saliva, prognostic algorithm reported as a risk score	Investigational
<b>0011A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0011M</b>	Oncology, prostate cancer, mRNA expression assay of 12 genes (10 content and 2 housekeeping), RT-PCR test utilizing blood plasma and urine, algorithms to predict high-grade prostate cancer risk	Investigational
<b>0012A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; second dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0013A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5 mL dosage; third dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0016M</b>	Oncology (bladder), mRNA, microarray gene expression profiling of 209 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as molecular subtype (luminal, luminal infiltrated, basal, basal claudin-low, neuroendocrine-like)	Investigational



<b>0018M</b>	Transplantation medicine (allograft rejection, renal), measurement of donor and third-party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	Investigational
<b>0019M</b>	Cardiovascular disease, plasma, analysis of protein biomarkers by aptamer-based microarray and algorithm reported as 4-year likelihood of coronary event in high-risk populations	Investigational
<b>0020M</b>	<b>Oncology (central nervous system), analysis of 30000 DNA methylation loci by methylation array, utilizing DNA extracted from tumor tissue, diagnostic algorithm reported as probability of matching a reference tumor subclass</b>	Investigational
<b>0024U</b>	Glycosylated acute phase proteins (GlycA), nuclear magnetic resonance spectroscopy, quantitative	Investigational
<b>0025U</b>	Tenofovir, by liquid chromatography with tandem mass spectrometry (LC-MS/MS), urine, quantitative	Investigational
<b>0031A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; single dose	Investigational COVID-19 Effective:(05/07/2023)
<b>0031U</b>	CYP1A2 (cytochrome P450 family 1, subfamily A, member 2)(eg, drug metabolism) gene analysis, common variants (ie, *1F, *1K, *6, *7)	Investigational

<b>0034A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage; booster dose	Investigational COVID-19 Effective:(05/07/2023)
<b>0034U</b>	TPMT (thiopurine S-methyltransferase), NUDT15 (nudix hydroxylase 15) (eg, thiopurine metabolism) gene analysis, common variants (ie, TPMT *2, *3A, *3B, *3C, *4, *5, *6, *8, *12; NUDT15 *3, *4, *5)	Investigational
<b>0035U</b>	Neurology (prion disease), cerebrospinal fluid, detection of prion protein by quaking-induced conformational conversion, qualitative	Investigational
<b>0038U</b>	Vitamin D, 25 hydroxy D2 and D3, by LC-MS/MS, serum microsample, quantitative	Investigational
<b>0039U</b>	Deoxyribonucleic acid (DNA) antibody, double stranded, high avidity	Investigational
<b>0041U</b>	Borrelia burgdorferi, antibody detection of 5 recombinant protein groups, by immunoblot, IgM	Investigational
<b>0042U</b>	Borrelia burgdorferi, antibody detection of 12 recombinant protein groups, by immunoblot, IgG	Investigational
<b>0043U</b>	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgM	Investigational
<b>0044U</b>	Tick-borne relapsing fever Borrelia group, antibody detection to 4 recombinant protein groups, by immunoblot, IgG	Investigational

<b>0045U</b>	Oncology (breast ductal carcinoma in situ), mRNA, gene expression profiling by real-time RT-PCR of 12 genes (7 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as recurrence score	Investigational
<b>0047U</b>	Oncology (prostate), mRNA, gene expression profiling by real-time RT-PCR of 17 genes (12 content and 5 housekeeping), utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a risk score	Investigational
<b>0048U</b>	Oncology (solid organ neoplasia), DNA, targeted sequencing of protein-coding exons of 468 cancer-associated genes, including interrogation for somatic mutations and microsatellite instability, matched with normal specimens, utilizing formalin-fixed paraffin-embedded tumor tissue, report of clinically significant mutation(s)	Investigational
<b>0050U</b>	Targeted genomic sequence analysis panel, acute myelogenous leukemia, DNA analysis, 194 genes, interrogation for sequence variants, copy number variants or rearrangements	Investigational
<b>0051A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0051U</b>	Prescription drug monitoring, evaluation of drugs present by liquid chromatography tandem mass spectrometry (LC-MS/MS), urine or blood, 31 drug panel, reported as quantitative results, detected or not detected, per date of service	Investigational

<b>0052A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; second dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0052U</b>	Lipoprotein, blood, high resolution fractionation and quantitation of lipoproteins, including all five major lipoprotein classes and subclasses of HDL, LDL, and VLDL by vertical auto profile ultracentrifugation	Investigational
<b>0053A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; third dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0054A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation; booster dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0054U</b>	Prescription drug monitoring, 14 or more classes of drugs and substances, definitive tandem mass spectrometry with chromatography, capillary blood, quantitative report with therapeutic and toxic ranges, including steady-state range for the prescribed dose when detected, per date of service	Investigational
<b>0055U</b>	Cardiology (heart transplant), cell-free DNA, PCR assay of 96 DNA target sequences (94 single nucleotide polymorphism targets and two control targets), plasma	Investigational

<b>0058U</b>	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus oncoprotein (small T antigen), serum, quantitative	Investigational
<b>0059U</b>	Oncology (Merkel cell carcinoma), detection of antibodies to the Merkel cell polyoma virus capsid protein (VP1), serum, reported as positive or negative	Investigational
<b>0060U</b>	Twin zygosity, genomic targeted sequence analysis of chromosome 2, using circulating cell-free fetal DNA in maternal blood	Investigational
<b>0061U</b>	Transcutaneous measurement of five biomarkers (tissue oxygenation [StO2], oxyhemoglobin [ctHbO2], deoxyhemoglobin [ctHbR], papillary and reticular dermal hemoglobin concentrations [ctHb1 and ctHb2]), using spatial frequency domain imaging (SFDI) and multi-spectral analysis	Investigational
<b>0062U</b>	Autoimmune (systemic lupus erythematosus), IgG and IgM analysis of 80 biomarkers, utilizing serum, algorithm reported with a risk score	Investigational
<b>0064A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, booster dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0067U</b>	Oncology (breast), immunohistochemistry, protein expression profiling of 4 biomarkers (matrix metalloproteinase-1 [MMP-1], carcinoembryonic antigen-related cell adhesion molecule 6 [CEACAM6], hyaluronoglucosaminidase [HYAL1], highly expressed in cancer protein [HEC1]), formalin-fixed paraffin-embedded precancerous breast tissue, algorithm reported as carcinoma risk score	Investigational

<b>0069U</b>	Oncology (colorectal), microRNA, RT-PCR expression profiling of miR-31-3p, formalin-fixed paraffin-embedded tissue, algorithm reported as an expression score	Investigational
<b>0071A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0071T</b>	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume less than 200 cc of tissue	Investigational
<b>0072A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0072T</b>	Focused ultrasound ablation of uterine leiomyomata, including MR guidance; total leiomyomata volume greater or equal to 200 cc of tissue	Investigational
<b>0073A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	Investigational COVID-19 Effective:(04/18/2023)

<b>0074A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; booster dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0075T</b>	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; initial vessel	Investigational
<b>0076T</b>	Transcatheter placement of extracranial vertebral artery stent(s), including radiologic supervision and interpretation, open or percutaneous; each additional vessel (List separately in addition to code for primary procedure)	Investigational
<b>0078U</b>	Pain management (opioid-use disorder) genotyping panel, 16 common variants (ie, ABCB1, COMT, DAT1, DBH, DOR, DRD1, DRD2, DRD4, GABA, GAL, HTR2A, HTTLPR, MTHFR, MUOR, OPRK1, OPRM1), buccal swab or other germline tissue sample, algorithm reported as positive or negative risk of opioid-use disorder	Investigational
<b>0080U</b>	Oncology (lung), mass spectrometric analysis of galectin-3-binding protein and scavenger receptor cysteine-rich type 1 protein M130, with five clinical risk factors (age, smoking status, nodule diameter, nodule-spiculation status and nodule location), utilizing plasma, algorithm reported as a categorical probability of malignancy	Investigational

<b>0081A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0082A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0082U</b>	Drug test(s), definitive, 90 or more drugs or substances, definitive chromatography with mass spectrometry, and presumptive, any number of drug classes, by instrument chemistry analyzer (utilizing immunoassay), urine, report of presence or absence of each drug, drug metabolite or substance with description and severity of significant interactions per date of service	Investigational
<b>0083A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; third dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0083U</b>	Oncology, response to chemotherapy drugs using motility contrast tomography, fresh or frozen tissue, reported as likelihood of sensitivity or resistance to drugs or drug combinations	Investigational



<b>0084U</b>	Red blood cell antigen typing, DNA, genotyping of 10 blood groups with phenotype prediction of 37 red blood cell antigens	Investigational
<b>0087U</b>	Cardiology (heart transplant), mRNA gene expression profiling by microarray of 1283 genes, transplant biopsy tissue, allograft rejection and injury algorithm reported as a probability score	Investigational
<b>0088U</b>	Transplantation medicine (kidney allograft rejection), microarray gene expression profiling of 1494 genes, utilizing transplant biopsy tissue, algorithm reported as a probability score for rejection	Investigational
<b>0089U</b>	Oncology (melanoma), gene expression profiling by RTqPCR, PRAME and LINC00518, superficial collection using adhesive patch(es)	Investigational
<b>0090U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 23 genes (14 content and 9 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	Investigational
<b>0091A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; first dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)
<b>0091U</b>	Oncology (colorectal) screening, cell enumeration of circulating tumor cells, utilizing whole blood, algorithm, for the presence of adenoma or cancer, reported as a positive or negative result	Investigational

<b>0092A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; second dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)
<b>0092U</b>	Oncology (lung), three protein biomarkers, immunoassay using magnetic nanosensor technology, plasma, algorithm reported as risk score for likelihood of malignancy	Investigational
<b>0093A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; third dose, when administered to individuals 6 through 11 years	Investigational COVID-19 Effective:(04/18/2023)
<b>0094A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage; booster dose, when administered to individuals 18 years and over Eosinophilic esophagitis (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis	Investigational COVID-19 Effective:(04/18/2023)

<b>0095U</b>	Eosinophilic esophagitis (Eotaxin-3 [CCL26 {C-C motif chemokine ligand 26}] and major basic protein [PRG2 {proteoglycan 2, pro eosinophil major basic protein}]), enzyme-linked immunosorbent assays (ELISA), specimen obtained by esophageal string test device, algorithm reported as probability of active or inactive eosinophilic esophagitis	Investigational
<b>0100T</b>	Placement of a subconjunctival retinal prosthesis receiver and pulse generator, and implantation of intra-ocular retinal electrode array, with vitrectomy	Investigational
<b>0101T</b>	Extracorporeal shock wave involving musculoskeletal system, not otherwise specified	Investigational
<b>0101U</b>	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (15 genes [sequencing and deletion/duplication], EPCAM and GREM1 [deletion/duplication only])	Investigational
<b>0102T</b>	Extracorporeal shock wave performed by a physician, requiring anesthesia other than local, and involving the lateral humeral epicondyle	Investigational
<b>0102U</b>	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (17 genes [sequencing and deletion/duplication])	Investigational

<b>0103U</b>	Hereditary ovarian cancer (eg, hereditary ovarian cancer, hereditary endometrial cancer), genomic sequence analysis panel utilizing a combination of NGS, Sanger, MLPA, and array CGH, with mRNA analytics to resolve variants of unknown significance when indicated (24 genes [sequencing and deletion/duplication], EPCAM [deletion/duplication only])	Investigational
<b>0105U</b>	Nephrology (chronic kidney disease), multiplex electrochemiluminescent immunoassay (ECLIA) of tumor necrosis factor receptor 1A, receptor superfamily 2 (TNFR1, TNFR2), and kidney injury molecule-1 (KIM-1) combined with longitudinal clinical data, including APOL1 genotype if available, and plasma (isolated fresh or frozen), algorithm reported as probability score for rapid kidney function decline (RKFD)	Investigational
<b>0106T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation	Investigational
<b>0106U</b>	Gastric emptying, serial collection of 7 timed breath specimens, non-radioisotope carbon-13 (13C) spirulina substrate, analysis of each specimen by gas isotope ratio mass spectrometry, reported as rate of 13CO2 excretion	Investigational
<b>0107T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation	Investigational
<b>0108T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational

<b>0108U</b>	Gastroenterology (Barrett's esophagus), whole slide-digital imaging, including morphometric analysis, computer-assisted quantitative immunolabeling of 9 protein biomarkers (p16, AMACR, p53, CD68, COX-2, CD45RO, HIF1a, HER-2, K20) and morphology, formalin-fixed paraffin-embedded tissue, algorithm reported as risk of progression to high-grade dysplasia or cancer	Investigational
<b>0109T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia	Investigational
<b>0110T</b>	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation	Investigational
<b>0110U</b>	Prescription drug monitoring, one or more oral oncology drug(s) and substances, definitive tandem mass spectrometry with chromatography, serum or plasma from capillary blood or venous blood, quantitative report with steady-state range for the prescribed drug(s) when detected	Investigational
<b>0111A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage; first dose	Investigational COVID-19 Effective:(04/18/2023)
<b>0112A</b>	Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage; second dose	Investigational COVID-19 Effective:(04/18/2023)

<b>0113U</b>	Oncology (prostate), measurement of PCA3 and TMPRSS2-ERG in urine and PSA in serum following prostatic massage, by RNA amplification and fluorescence-based detection, algorithm reported as risk score	Investigational
<b>0114U</b>	Gastroenterology (Barrett's esophagus), VIM and CCNA1 methylation analysis, esophageal cells, algorithm reported as likelihood for Barrett's esophagus	Investigational
<b>0118U</b>	Transplantation medicine, quantification of donor-derived cell-free DNA using whole genome next-generation sequencing, plasma, reported as percentage of donor-derived cell-free DNA in the total cell-free DNA	Investigational
<b>0119U</b>	Cardiology, ceramides by liquid chromatography-tandem mass spectrometry, plasma, quantitative report with risk score for major cardiovascular events	Investigational
<b>0120U</b>	Oncology (B-cell lymphoma classification), mRNA, gene expression profiling by fluorescent probe hybridization of 58 genes (45 content and 13 housekeeping genes), formalin-fixed paraffin-embedded tissue, algorithm reported as likelihood for primary mediastinal B-cell lymphoma (PMBCL) and diffuse large B-cell lymphoma (DLBCL) with cell of origin subtyping in the latter	Investigational
<b>0121U</b>	Sickle cell disease, microfluidic flow adhesion (VCAM-1), whole blood	Investigational
<b>0122U</b>	Sickle cell disease, microfluidic flow adhesion (P-Selectin), whole blood	Investigational
<b>0123U</b>	Mechanical fragility, RBC, shear stress and spectral analysis profiling	Investigational

<b>0130U</b>	Hereditary colon cancer disorders (eg, Lynch syndrome, PTEN hamartoma syndrome, Cowden syndrome, familial adenomatosis polyposis), targeted mRNA sequence analysis panel (APC, CDH1, CHEK2, MLH1, MSH2, MSH6, MUTYH, PMS2, PTEN, and TP53) (List separately in addition to code for primary procedure)	Investigational
<b>0131U</b>	Hereditary breast cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (13 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0132U</b>	Hereditary ovarian cancer-related disorders (eg, hereditary breast cancer, hereditary ovarian cancer, hereditary endometrial cancer), targeted mRNA sequence analysis panel (17 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0133U</b>	Hereditary prostate cancer-related disorders, targeted mRNA sequence analysis panel (11 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0134U</b>	Hereditary pan cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (18 genes) (List separately in addition to code for primary procedure)	Investigational
<b>0135U</b>	Hereditary gynecological cancer (eg, hereditary breast and ovarian cancer, hereditary endometrial cancer, hereditary colorectal cancer), targeted mRNA sequence analysis panel (12 genes) (List separately in addition to code for primary procedure)	Investigational

<b>0136U</b>	ATM (ataxia telangiectasia mutated) (eg, ataxia telangiectasia) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0137U</b>	PALB2 (partner and localizer of BRCA2) (eg, breast and pancreatic cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0138U</b>	BRCA1 (BRCA1, DNA repair associated), BRCA2 (BRCA2, DNA repair associated) (eg, hereditary breast and ovarian cancer) mRNA sequence analysis (List separately in addition to code for primary procedure)	Investigational
<b>0152U</b>	Infectious disease (bacteria, fungi, parasites, and DNA viruses), microbial cell-free DNA, plasma, untargeted next-generation sequencing, report for significant positive pathogens	Investigational
<b>0153U</b>	Oncology (breast), mRNA, gene expression profiling by next-generation sequencing of 101 genes, utilizing formalin-fixed paraffin-embedded tissue, algorithm reported as a triple negative breast cancer clinical subtype(s) with information on immune cell involvement	Investigational
<b>0163T</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational



<b>0163U</b>	Oncology (colorectal) screening, biochemical enzyme-linked immunosorbent assay (ELISA) of 3 plasma or serum proteins (teratocarcinoma derived growth factor-1 [TDGF-1, Cripto-1], carcinoembryonic antigen [CEA], extracellular matrix protein [ECM]), with demographic data (age, gender, CRC-screening compliance) using a proprietary algorithm and reported as likelihood of CRC or advanced adenomas	Investigational
<b>0164T</b>	Removal of total disc arthroplasty, (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational
<b>0164U</b>	Gastroenterology (irritable bowel syndrome [IBS]), immunoassay for anti-CdtB and anti-vinculin antibodies, utilizing plasma, algorithm for elevated or not elevated qualitative results	Investigational
<b>0165T</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, each additional interspace, lumbar (List separately in addition to code for primary procedure)	Investigational
<b>0165U</b>	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, individual epitope results and probability of peanut allergy	Investigational
<b>0166U</b>	Liver disease, 10 biochemical assays (a2-macroglobulin, haptoglobin, apolipoprotein A1, bilirubin, GGT, ALT, AST, triglycerides, cholesterol, fasting glucose) and biometric and demographic data, utilizing serum, algorithm reported as scores for fibrosis, necroinflammatory activity, and steatosis with a summary interpretation	Investigational

<b>0169U</b>	NUDT15 (nudix hydrolase 15) and TPMT (thiopurine S-methyltransferase) (eg, drug metabolism) gene analysis, common variants	Investigational
<b>0170U</b>	Neurology (autism spectrum disorder [ASD]), RNA, next-generation sequencing, saliva, algorithmic analysis, and results reported as predictive probability of ASD diagnosis	Investigational
<b>0171U</b>	Targeted genomic sequence analysis panel, acute myeloid leukemia, myelodysplastic syndrome, and myeloproliferative neoplasms, DNA analysis, 23 genes, interrogation for sequence variants, rearrangements and minimal residual disease, reported as presence/absence	Investigational
<b>0174U</b>	Oncology (solid tumor), mass spectrometric 30 protein targets, formalin-fixed paraffin-embedded tissue, prognostic and predictive algorithm reported as likely, unlikely, or uncertain benefit of 39 chemotherapy and targeted therapeutic oncology agents	Investigational
<b>0176U</b>	Cytotoxic distending toxin B (CdtB) and vinculin IgG antibodies by immunoassay (ie, ELISA)	Investigational
<b>0178U</b>	Peanut allergen-specific quantitative assessment of multiple epitopes using enzyme-linked immunosorbent assay (ELISA), blood, report of minimum eliciting exposure for a clinical reaction	Investigational
<b>0179U</b>	Oncology (non-small cell lung cancer), cell-free DNA, targeted sequence analysis of 23 genes (single nucleotide variations, insertions and deletions, fusions without prior knowledge of partner/breakpoint, copy number variations), with report of significant mutation(s)	Investigational

<b>0180U</b>	Red cell antigen (ABO blood group) genotyping (ABO), gene analysis Sanger/chain termination/conventional sequencing, ABO (ABO, alpha 1-3-N-acetylgalactosaminyltransferase and alpha 1-3-galactosyltransferase) gene, including subtyping, 7 exons	Investigational
<b>0181U</b>	Red cell antigen (Colton blood group) genotyping (CO), gene analysis, AQP1 (aquaporin 1 [Colton blood group]) exon 1	Investigational
<b>0182U</b>	Red cell antigen (Cromer blood group) genotyping (CROM), gene analysis, CD55 (CD55 molecule [Cromer blood group]) exons 1-10	Investigational
<b>0183U</b>	Red cell antigen (Diego blood group) genotyping (DI), gene analysis, SLC4A1 (solute carrier family 4 member 1 [Diego blood group]) exon 19	Investigational
<b>0184U</b>	Red cell antigen (Dombrock blood group) genotyping (DO), gene analysis, ART4 (ADP-ribosyltransferase 4 [Dombrock blood group]) exon 2	Investigational
<b>0185U</b>	Red cell antigen (H blood group) genotyping (FUT1), gene analysis, FUT1 (fucosyltransferase 1 [H blood group]) exon 4	Investigational
<b>0186U</b>	Red cell antigen (H blood group) genotyping (FUT2), gene analysis, FUT2 (fucosyltransferase 2) exon 2	Investigational
<b>0187U</b>	Red cell antigen (Duffy blood group) genotyping (FY), gene analysis, ACKR1 (atypical chemokine receptor 1 [Duffy blood group]) exons 1-2	Investigational
<b>0188U</b>	Red cell antigen (Gerbich blood group) genotyping (GE), gene analysis, GYPC (glycophorin C [Gerbich blood group]) exons 1-4	Investigational
<b>0189U</b>	Red cell antigen (MNS blood group) genotyping (GYPA), gene analysis, GYPA (glycophorin A [MNS blood group]) introns 1, 5, exon 2	Investigational

<b>0190U</b>	Red cell antigen (MNS blood group) genotyping (GYPB), gene analysis, GYPB (glycophorin B [MNS blood group]) introns 1, 5, pseudoexon 3	Investigational
<b>0191U</b>	Red cell antigen (Indian blood group) genotyping (IN), gene analysis, CD44 (CD44 molecule [Indian blood group]) exons 2, 3, 6	Investigational
<b>0192U</b>	Red cell antigen (Kidd blood group) genotyping (JK), gene analysis, SLC14A1 (solute carrier family 14 member 1 [Kidd blood group]) gene promoter, exon 9	Investigational
<b>0193U</b>	Red cell antigen (JR blood group) genotyping (JR), gene analysis, ABCG2 (ATP binding cassette subfamily G member 2 [Junior blood group]) exons 2-26	Investigational
<b>0194U</b>	Red cell antigen (Kell blood group) genotyping (KEL), gene analysis, KEL (Kell metallo-endorpeptidase [Kell blood group]) exon 8	Investigational
<b>0195U</b>	KLF1 (Kruppel-like factor 1), targeted sequencing (ie, exon 13)	Investigational
<b>0196U</b>	Red cell antigen (Lutheran blood group) genotyping (LU), gene analysis, BCAM (basal cell adhesion molecule [Lutheran blood group]) exon 3	Investigational
<b>0197U</b>	Red cell antigen (Landsteiner-Wiener blood group) genotyping (LW), gene analysis, ICAM4 (intercellular adhesion molecule 4 [Landsteiner-Wiener blood group]) exon 1	Investigational
<b>0198U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis Sanger/chain termination/conventional sequencing, RHD (Rh blood group D antigen) exons 1-10 and RHCE (Rh blood group CcEe antigens) exon 5	Investigational
<b>0199U</b>	Red cell antigen (Scianna blood group) genotyping (SC), gene analysis, ERMAP (erythroblast membrane associated protein [Scianna blood group]) exons 4, 12	Investigational

<b>0200U</b>	Red cell antigen (Kx blood group) genotyping (XK), gene analysis, XK (X-linked Kx blood group) exons 1-3	Investigational
<b>0201U</b>	Red cell antigen (Yt blood group) genotyping (YT), gene analysis, ACHE (acetylcholinesterase [Cartwright blood group]) exon 2	Investigational
<b>0202T</b>	Posterior vertebral joint(s) arthroplasty (eg, facet joint[s] replacement), including facetectomy, laminectomy, foraminotomy, and vertebral column fixation, injection of bone cement, when performed, including fluoroscopy, single level, lumbar spine	Investigational
<b>0203U</b>	Autoimmune (inflammatory bowel disease), mRNA, gene expression profiling by quantitative RT-PCR, 17 genes (15 target and 2 reference genes), whole blood, reported as a continuous risk score and classification of inflammatory bowel disease aggressiveness	Investigational
<b>0205U</b>	Ophthalmology (age-related macular degeneration), analysis of 3 gene variants (2 CFH gene, 1 ARMS2 gene), using PCR and MALDI-TOF, buccal swab, reported as positive or negative for neovascular age-related macular-degeneration risk associated with zinc supplements	Investigational
<b>0206U</b>	Neurology (Alzheimer disease); cell aggregation using morphometric imaging and protein kinase C-epsilon (PKCe) concentration in response to amylospheroid treatment by ELISA, cultured skin fibroblasts, each reported as positive or negative for Alzheimer disease	Investigational
<b>0207T</b>	Evacuation of meibomian glands, automated, using heat and intermittent pressure, unilateral	Investigational

<b>0207U</b>	Neurology (Alzheimer disease); quantitative imaging of phosphorylated ERK1 and ERK2 in response to bradykinin treatment by in situ immunofluorescence, using cultured skin fibroblasts, reported as a probability index for Alzheimer disease (List separately in addition to code for primary procedure)	Investigational
<b>0209U</b>	Cytogenomic constitutional (genome-wide) analysis, interrogation of genomic regions for copy number, structural changes and areas of homozygosity for chromosomal abnormalities	Investigational
<b>0211U</b>	Oncology (pan-tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded tissue, interpretative report for single nucleotide variants, copy number alterations, tumor mutational burden, and microsatellite instability, with therapy association	Investigational
<b>0216U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 12 common genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational
<b>0217U</b>	Neurology (inherited ataxias), genomic DNA sequence analysis of 51 genes including small sequence changes, deletions, duplications, short tandem repeat gene expansions, and variants in non-uniquely mappable regions, blood or saliva, identification and categorization of genetic variants	Investigational

<b>0218U</b>	Neurology (muscular dystrophy), DMD gene sequence analysis, including small sequence changes, deletions, duplications, and variants in non-uniquely mappable regions, blood or saliva, identification and characterization of genetic variants	Investigational
<b>0219U</b>	Infectious agent (human immunodeficiency virus), targeted viral next-generation sequence analysis (ie, protease [PR], reverse transcriptase [RT], integrase [INT]), algorithm reported as prediction of antiviral drug susceptibility	Investigational
<b>0220U</b>	Red cell antigen (RH blood group) genotyping (RHD and RHCE), gene analysis, next-generation sequencing, RH proximal promoter, exons 1-10, portions of introns 2-3	Investigational
<b>0227U</b>	Drug assay, presumptive, 30 or more drugs or metabolites, urine, liquid chromatography with tandem mass spectrometry (LC-MS/MS) using multiple reaction monitoring (MRM), with drug or metabolite description, includes sample validation	Investigational
<b>0228U</b>	Oncology (prostate), multianalyte molecular profile by photometric detection of macromolecules adsorbed on nanosponge array slides with machine learning, utilizing first morning voided urine, algorithm reported as likelihood of prostate cancer	Investigational
<b>0229U</b>	BCAT1 (Branched chain amino acid transaminase 1) and IKZF1 (IKAROS family zinc finger 1) (eg, colorectal cancer) promoter methylation analysis	Investigational
<b>0232T</b>	Injection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed	Investigational

<b>0243U</b>	Obstetrics (preeclampsia), biochemical assay of placental-growth factor, time-resolved fluorescence immunoassay, maternal serum, predictive algorithm reported as a risk score for preeclampsia	Investigational
<b>0244U</b>	Oncology (solid organ), DNA, comprehensive genomic profiling, 257 genes, interrogation for single-nucleotide variants, insertions/deletions, copy number alterations, gene rearrangements, tumor-mutational burden and microsatellite instability, utilizing formalin-fixed paraffin-embedded tumor tissue	Investigational
<b>0247U</b>	Obstetrics (preterm birth), insulin-like growth factor-binding protein 4 (IBP4), sex hormone-binding globulin (SHBG), quantitative measurement by LC-MS/MS, utilizing maternal serum, combined with clinical data, reported as predictive-risk stratification for spontaneous preterm birth	Investigational
<b>0248U</b>	Oncology (brain), spheroid cell culture in a 3D microenvironment, 12 drug panel, tumor-response prediction for each drug	Investigational
<b>0249U</b>	Oncology (breast), semiquantitative analysis of 32 phosphoproteins and protein analytes, includes laser capture microdissection, with algorithmic analysis and interpretative report	Investigational
<b>0250U</b>	Oncology (solid organ neoplasm), targeted genomic sequence DNA analysis of 505 genes, interrogation for somatic alterations (SNVs [single nucleotide variant], small insertions and deletions, one amplification, and four translocations), microsatellite instability and tumor-mutation burden	Investigational



<b>0251U</b>	Hepcidin-25, enzyme-linked immunosorbent assay (ELISA), serum or plasma	Investigational
<b>0252U</b>	Fetal aneuploidy short tandem-repeat comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploidy	Investigational
<b>0253T</b>	Insertion of anterior segment aqueous drainage device, without extraocular reservoir, internal approach, into the suprachoroidal space	Investigational
<b>0253U</b>	Reproductive medicine (endometrial receptivity analysis), RNA gene expression profile, 238 genes by next-generation sequencing, endometrial tissue, predictive algorithm reported as endometrial window of implantation (eg, pre-receptive, receptive, post-receptive)	Investigational
<b>0255U</b>	Andrology (infertility), sperm-capacitation assessment of ganglioside GM1 distribution patterns, fluorescence microscopy, fresh or frozen specimen, reported as percentage of capacitated sperm and probability of generating a pregnancy score	Investigational
<b>0258U</b>	Autoimmune (psoriasis), mRNA, next-generation sequencing, gene expression profiling of 50-100 genes, skin-surface collection using adhesive patch, algorithm reported as likelihood of response to psoriasis biologics	Investigational
<b>0259U</b>	Nephrology (chronic kidney disease), nuclear magnetic resonance spectroscopy measurement of myoinositol, valine, and creatinine, algorithmically combined with cystatin C (by immunoassay) and demographic data to determine estimated glomerular filtration rate (GFR), serum, quantitative	Investigational

<b>0260U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational
<b>0261U</b>	Oncology (colorectal cancer), image analysis with artificial intelligence assessment of 4 histologic and immunohistochemical features (CD3 and CD8 within tumor-stroma border and tumor core), tissue, reported as immune response and recurrence-risk score	Investigational
<b>0262U</b>	Oncology (solid tumor), gene expression profiling by real-time RT-PCR of 7 gene pathways (ER, AR, PI3K, MAPK, HH, TGFB, Notch), formalin-fixed paraffin-embedded (FFPE), algorithm reported as gene pathway activity score	Investigational
<b>0263T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure including unilateral or bilateral bone marrow harvest	Investigational
<b>0263U</b>	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 16 central carbon metabolites (ie, a-ketoglutarate, alanine, lactate, phenylalanine, pyruvate, succinate, carnitine, citrate, fumarate, hypoxanthine, inosine, malate, S-sulfocysteine, taurine, urate, and xanthine), liquid chromatography tandem mass spectrometry (LC-MS/MS), plasma, algorithmic analysis with result reported as negative or positive (with metabolic subtypes of ASD)	Investigational

<b>0264T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; complete procedure excluding bone marrow harvest	Investigational
<b>0264U</b>	Rare diseases (constitutional/heritable disorders), identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping	Investigational
<b>0265T</b>	Intramuscular autologous bone marrow cell therapy, with preparation of harvested cells, multiple injections, one leg, including ultrasound guidance, if performed; unilateral or bilateral bone marrow harvest only for intramuscular autologous bone marrow cell therapy	Investigational
<b>0266T</b>	Implantation or replacement of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0266U</b>	Unexplained constitutional or other heritable disorders or syndromes, tissue-specific gene expression by whole-transcriptome and next-generation sequencing, blood, formalin-fixed paraffin-embedded (FFPE) tissue or fresh frozen tissue, reported as presence or absence of splicing or expression changes	Investigational
<b>0267T</b>	Implantation or replacement of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational

<b>0267U</b>	Rare constitutional and other heritable disorders, identification of copy number variations, inversions, insertions, translocations, and other structural variants by optical genome mapping and whole genome sequencing	Investigational
<b>0268T</b>	Implantation or replacement of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0269T</b>	Revision or removal of carotid sinus baroreflex activation device; total system (includes generator placement, unilateral or bilateral lead placement, intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0270T</b>	Revision or removal of carotid sinus baroreflex activation device; lead only, unilateral (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0271T</b>	Revision or removal of carotid sinus baroreflex activation device; pulse generator only (includes intra-operative interrogation, programming, and repositioning, when performed)	Investigational
<b>0272T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day);	Investigational

<b>0273T</b>	Interrogation device evaluation (in person), carotid sinus baroreflex activation system, including telemetric iterative communication with the implantable device to monitor device diagnostics and programmed therapy values, with interpretation and report (eg, battery status, lead impedance, pulse amplitude, pulse width, therapy frequency, pathway mode, burst mode, therapy start/stop times each day); with programming	Investigational
<b>0274T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; cervical or thoracic	Investigational
<b>0275T</b>	Percutaneous laminotomy/laminectomy (interlaminar approach) for decompression of neural elements, (with or without ligamentous resection, discectomy, facetectomy and/or foraminotomy), any method, under indirect image guidance (eg, fluoroscopic, CT), single or multiple levels, unilateral or bilateral; lumbar	Investigational
<b>0278T</b>	Transcutaneous electrical modulation pain reprocessing (eg, scrambler therapy), each treatment session (includes placement of electrodes)	Investigational
<b>0285U</b>	Oncology, response to radiation, cell-free DNA, quantitative branched chain DNA amplification, plasma, reported as a radiation toxicity score	Investigational

<b>0288U</b>	Oncology (lung), mRNA, quantitative PCR analysis of 11 genes (BAG1, BRCA1, CDC6, CDK2AP1, ERBB3, FUT3, IL11, LCK, RND3, SH3BGR, WNT3A) and 3 reference genes (ESD, TBP, YAP1), formalin-fixed paraffin-embedded (FFPE) tumor tissue, algorithmic interpretation reported as a recurrence risk score	Investigational
<b>0289U</b>	Neurology (Alzheimer disease), mRNA, gene expression profiling by RNA sequencing of 24 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0290U</b>	Pain management, mRNA, gene expression profiling by RNA sequencing of 36 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0291U</b>	Psychiatry (mood disorders), mRNA, gene expression profiling by RNA sequencing of 144 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0292U</b>	Psychiatry (stress disorders), mRNA, gene expression profiling by RNA sequencing of 72 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0293U</b>	Psychiatry (suicidal ideation), mRNA, gene expression profiling by RNA sequencing of 54 genes, whole blood, algorithm reported as predictive risk score	Investigational
<b>0294U</b>	Longevity and mortality risk, mRNA, gene expression profiling by RNA sequencing of 18 genes, whole blood, algorithm reported as predictive risk score	Investigational

<b>0295U</b>	Oncology (breast ductal carcinoma in situ), protein expression profiling by immunohistochemistry of 7 proteins (COX2, FOXA1, HER2, Ki-67, p16, PR, SIAH2), with 4 clinicopathologic factors (size, age, margin status, palpability), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a recurrence risk score	Investigational
<b>0296U</b>	Oncology (oral and/or oropharyngeal cancer), gene expression profiling by RNA sequencing at least 20 molecular features (eg, human and/or microbial mRNA), saliva, algorithm reported as positive or negative for signature associated with malignancy	Investigational
<b>0297U</b>	Oncology (pan tumor), whole genome sequencing of paired malignant and normal DNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and variant identification	Investigational
<b>0298U</b>	Oncology (pan tumor), whole transcriptome sequencing of paired malignant and normal RNA specimens, fresh or formalin-fixed paraffin-embedded (FFPE) tissue, blood or bone marrow, comparative sequence analyses and expression level and chimeric transcript identification	Investigational
<b>0299U</b>	Oncology (pan tumor), whole genome optical genome mapping of paired malignant and normal DNA specimens, fresh frozen tissue, blood, or bone marrow, comparative structural variant identification	Investigational

<b>0300U</b>	Oncology (pan tumor), whole genome sequencing and optical genome mapping of paired malignant and normal DNA specimens, fresh tissue, blood, or bone marrow, comparative sequence analyses and variant identification	Investigational
<b>0303U</b>	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; hypoxic	Investigational
<b>0304U</b>	Hematology, red blood cell (RBC) adhesion to endothelial/subendothelial adhesion molecules, functional assessment, whole blood, with algorithmic analysis and result reported as an RBC adhesion index; normoxic	Investigational
<b>0305U</b>	Hematology, red blood cell (RBC) functionality and deformity as a function of shear stress, whole blood, reported as a maximum elongation index	Investigational
<b>0306U</b>	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis, cell-free DNA, initial (baseline) assessment to determine a patient specific panel for future comparisons to evaluate for MRD	Investigational
<b>0307U</b>	Oncology (minimal residual disease [MRD]), next-generation targeted sequencing analysis of a patient-specific panel, cell-free DNA, subsequent assessment with comparison to previously analyzed patient specimens to evaluate for MRD	Investigational



<b>0308U</b>	Cardiology (coronary artery disease [CAD]), analysis of 3 proteins (high sensitivity [hs] troponin, adiponectin, and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for obstructive CAD	Investigational
<b>0309U</b>	Cardiology (cardiovascular disease), analysis of 4 proteins (NT-proBNP, osteopontin, tissue inhibitor of metalloproteinase-1 [TIMP-1], and kidney injury molecule-1 [KIM-1]), plasma, algorithm reported as a risk score for major adverse cardiac event	Investigational
<b>0310U</b>	Pediatrics (vasculitis, Kawasaki disease [KD]), analysis of 3 biomarkers (NT-proBNP, C-reactive protein, and T-uptake), plasma, algorithm reported as a risk score for KD	Investigational
<b>0311U</b>	Infectious disease (bacterial), quantitative antimicrobial susceptibility reported as phenotypic minimum inhibitory concentration (MIC)-based antimicrobial susceptibility for each organisms identified	Investigational
<b>0312U</b>	Autoimmune diseases (eg, systemic lupus erythematosus [SLE]), analysis of 8 IgG autoantibodies and 2 cell-bound complement activation products using enzyme-linked immunosorbent immunoassay (ELISA), flow cytometry and indirect immunofluorescence, serum, or plasma and whole blood, individual components reported along with an algorithmic SLE-likelihood assessment	Investigational

<b>0313U</b>	Oncology (pancreas), DNA and mRNA next-generation sequencing analysis of 74 genes and analysis of CEA (CEACAM5) gene expression, pancreatic cyst fluid, algorithm reported as a categorical result (ie, negative, low probability of neoplasia or positive, high probability of neoplasia)	Investigational
<b>0314U</b>	Oncology (cutaneous melanoma), mRNA gene expression profiling by RT-PCR of 35 genes (32 content and 3 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical result (ie, benign, intermediate, malignant)	Investigational
<b>0315U</b>	Oncology (cutaneous squamous cell carcinoma), mRNA gene expression profiling by RT-PCR of 40 genes (34 content and 6 housekeeping), utilizing formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as a categorical risk result (ie, Class 1, Class 2A, Class 2B)	Investigational
<b>0316U</b>	Borrelia burgdorferi (Lyme disease), OspA protein evaluation, urine	Investigational
<b>0317U</b>	Oncology (lung cancer), four-probe FISH (3q29, 3p22.1, 10q22.3, 10cen) assay, whole blood, predictive algorithm-generated evaluation reported as decreased or increased risk for lung cancer	Investigational
<b>0318U</b>	Pediatrics (congenital epigenetic disorders), whole genome methylation analysis by microarray for 50 or more genes, blood	Investigational
<b>0319U</b>	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using pretransplant peripheral blood, algorithm reported as a risk score for early acute rejection	Investigational

<b>0320U</b>	Nephrology (renal transplant), RNA expression by select transcriptome sequencing, using posttransplant peripheral blood, algorithm reported as a risk score for acute cellular rejection	Investigational
<b>0321U</b>	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 20 bacterial and fungal organisms and identification of 16 associated antibiotic-resistance genes, multiplex amplified probe technique	Investigational
<b>0322U</b>	Neurology (autism spectrum disorder [ASD]), quantitative measurements of 14 acyl carnitines and microbiome-derived metabolites, liquid chromatography with tandem mass spectrometry (LC-MS/MS), plasma, results reported as negative or positive for risk of metabolic subtypes associated with ASD	Investigational
<b>0323U</b>	Infectious agent detection by nucleic acid (DNA and RNA), central nervous system pathogen, metagenomic next-generation sequencing, Cerebrospinal fluid (CSF), identification of pathogenic bacteria, viruses, parasites or fungi	Investigational
<b>0328U</b>	Drug assay, definitive, 120 or more drugs and metabolites, urine, quantitative liquid chromatography with tandem mass spectrometry (LC-MS/MS), includes specimen validity and algorithmic analysis describing drug or metabolite and presence or absence of risks for a significant patient adverse event, per date of service	Investigational

<b>0329U</b>	Oncology (neoplasia), exome and transcriptome sequence analysis for sequence variants, gene copy number amplifications and deletions, gene rearrangements, microsatellite instability and tumor mutational burden utilizing DNA and RNA from tumor with and DNA from normal blood or saliva for subtraction, report of clinically significant mutation(s) with therapy associations	Investigational
<b>0330U</b>	Infectious agent detection by nucleic acid (DNA or RNA), vaginal pathogen panel, identification of 27 organisms, amplified probe technique, vaginal swab	Investigational
<b>0330T</b>	Tear film imaging, unilateral or bilateral, with interpretation and report	Investigational
<b>0331U</b>	Oncology (hematolymphoid neoplasia), optical for copy number alterations and gene rearrangements utilizing DNA from blood or bone marrow, report of clinically significant alternations	Investigational
<b>0332T</b>	Myocardial sympathetic innervation imaging, planar qualitative and quantitative assessment; with tomographic SPECT	Investigational
<b>0332U</b>	Oncology (pan-tumor), genetic profiling of 8 DNA-regulatory (epigenetic) markers by quantitative polymerase chain reaction (qPCR), whole blood, reported as a high or low probability of responding to immune checkpoint-inhibitor therapy	Investigational

<b>0333U</b>	Oncology (liver), surveillance for hepatocellular carcinoma (HCC) in highrisk patients, analysis of methylation patterns on circulating cell-free DNA (cfDNA) plus measurement of serum of AFP/AFP-L3 and oncoprotein des-gammaprothrombin (DCP), algorithm reported as normal or abnormal result	Investigational
<b>0334U</b>	Oncology (solid organ), targeted genomic sequence analysis, formalin-fixed paraffinembedded (FFPE) tumor tissue, DNA analysis, 84 or more genes, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability and tumor mutational burden	Investigational
<b>0335T</b>	Insertion of sinus tarsi implant	Investigational
<b>0335U</b>	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, fetal sample, identification and categorization of genetic variants	Investigational

<b>0336U</b>	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis, including small sequence changes, copy number variants, deletions, duplications, mobile element insertions, uniparental disomy (UPD), inversions, aneuploidy, mitochondrial genome sequence analysis with heteroplasmy and large deletions, short tandem repeat (STR) gene expansions, blood or saliva, identification and categorization of genetic variants, each comparator genome (eg, parent)	Investigational
<b>0337U</b>	Oncology (plasma cell disorders and myeloma), circulating plasma cell immunologic selection, identification, morphological characterization, and enumeration of plasma cells based on differential CD138, CD38, CD19, and CD45 protein biomarker expression, peripheral blood	Investigational
<b>0338T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; unilateral	Investigational
<b>0338U</b>	Oncology (solid tumor), circulating tumor cell selection, identification, morphological characterization, detection and enumeration based on differential EpCAM, cytokeratins 8, 18, and 19, and CD45 protein biomarkers, and quantification of HER2 protein biomarker-expressing cells, peripheral blood	Investigational

<b>0339T</b>	Transcatheter renal sympathetic denervation, percutaneous approach including arterial puncture, selective catheter placement(s) renal artery(ies), fluoroscopy, contrast injection(s), intraprocedural roadmapping and radiological supervision and interpretation, including pressure gradient measurements, flush aortogram and diagnostic renal angiography when performed; bilateral	Investigational
<b>0339U</b>	Oncology (prostate), mRNA expression profiling of HOXC6 and DLX1, reverse transcription polymerase chain reaction (RT-PCR), first-void urine following digital rectal examination, algorithm reported as probability of high-grade cancer	Investigational
<b>0340U</b>	Oncology (pan-cancer), analysis of minimal residual disease (MRD) from plasma, with assays personalized to each patient based on prior next-generation sequencing of the patient's tumor and germline DNA, reported as absence or presence of MRD, with disease-burden correlation, if appropriate	Investigational
<b>0341U</b>	Fetal aneuploidy DNA sequencing comparative analysis, fetal DNA from products of conception, reported as normal (euploidy), monosomy, trisomy, or partial deletion/duplication, mosaicism, and segmental aneuploid	Investigational
<b>0342U</b>	Oncology (pancreatic cancer), multiplex immunoassay of C5, C4, cystatin C, factor B, osteoprotegerin (OPG), gelsolin, IGFBP3, CA125 and multiplex electrochemiluminescent immunoassay (ECLIA) for CA19-9, serum, diagnostic algorithm reported qualitatively as positive, negative, or borderline	Investigational

<b>0343U</b>	Oncology (prostate), exosome-based analysis of 442 small noncoding RNAs (sncRNAs) by quantitative reverse transcription polymerase chain reaction (RT-qPCR), urine, reported as molecular evidence of no-, low-, intermediate- or high-risk of prostate cancer	Investigational
<b>0344U</b>	Hepatology (nonalcoholic fatty liver disease [NAFLD]), semiquantitative evaluation of 28 lipid markers by liquid chromatography with tandem mass spectrometry (LC-MS/MS), serum, reported as at-risk for nonalcoholic steatohepatitis (NASH) or not NASH	Investigational
<b>0345U</b>	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6	Investigational
<b>0346U</b>	Beta amyloid, AB40 and AB42 by liquid chromatography with tandem mass spectrometry (LC-MS/MS), ratio, plasma	Investigational
<b>0347U</b>	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 16 gene report, with variant analysis and reported phenotypes	Investigational
<b>0348U</b>	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 25 gene report, with variant analysis and reported phenotypes	Investigational
<b>0349U</b>	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis, including reported phenotypes and impacted gene-drug interactions	Investigational



<b>0350U</b>	Drug metabolism or processing (multiple conditions), whole blood or buccal specimen, DNA analysis, 27 gene report, with variant analysis and reported phenotypes	Investigational
<b>0351U</b>	Infectious disease (bacterial or viral), biochemical assays, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), interferon gamma-induced protein-10 (IP-10), and C- reactive protein, serum, or venous whole blood, algorithm reported as likelihood of bacterial infection	Investigational
<b>0352U</b>	Infectious disease (bacterial vaginosis and vaginitis), multiplex amplified probe technique, for detection of bacterial vaginosis-associated bacteria (BVAB-2, Atopobium vaginae, and Megasphaera type 1), algorithm reported as detected or not detected and separate detection of Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata/Candida krusei, and trichomonas vaginalis, vaginal-fluid specimen, each result reported as detected or not detected	Investigational
<b>0355U</b>	APOL1 (apolipoprotein L1) (eg, chronic kidney disease), risk variants (G1, G2)	Investigational
<b>0356U</b>	Oncology (oropharyngeal or anal), evaluation of 17 DNA biomarkers using droplet digital PCR (ddPCR), cell-free DNA, algorithm reported as a prognostic risk score for cancer recurrence	Investigational
<b>0358U</b>	Neurology (mild cognitive impairment), analysis of $\beta$ -amyloid 1-42 and 1-40, chemiluminescence enzyme immunoassay, cerebral spinal fluid, reported as positive, likely positive, or negative	Investigational

<b>0359U</b>	Oncology (prostate cancer), analysis of all prostate-specific antigen (PSA) structural isoforms by phase separation and immunoassay, plasma, algorithm reports risk of cancer	Investigational
<b>0360U</b>	Oncology (lung), enzyme-linked immunosorbent assay (ELISA) of 7 autoantibodies (p53, NY-ESO-1, CAGE, GBU4-5, SOX2, MAGE A4, and HuD), plasma, algorithm reported as a categorical result for risk of malignancy	Investigational
<b>0361U</b>	Neurofilament light chain, digital immunoassay, plasma, quantitative	Investigational
<b>0362U</b>	Oncology (papillary thyroid cancer), gene-expression profiling via targeted hybrid capture-enrichment RNA sequencing of 82 content genes fine needle aspiration or formalin-fixed paraffin embedded (FFPE) tissue, algorithm reported as one of three molecular subtypes	Investigational
<b>0363U</b>	Oncology (urothelial), mRNA, geneexpression profiling by real-time quantitative PCR of 5 genes (MDK, HOXA13, CDC2 [CDK1], IGFBP5, and CXCR2), utilizing urine, algorithm incorporates age, sex, smoking history, and macrohematuria frequency, reported as a risk score for having urothelial carcinoma	Investigational
<b>0364U</b>	Oncology (hematolymphoid neoplasm), genomic sequence analysis using multiplex (PCR) and next-generation sequencing with algorithm, quantification of dominant clonal sequence(s), reported as presence or absence of minimal residual disease (MRD) with quantitation of disease burden, when appropriate	Investigational

<b>0365U</b>	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of bladder cancer	Investigational
<b>0366U</b>	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, algorithm reported as a probability of recurrent bladder cancer	Investigational
<b>0367U</b>	Oncology (bladder), analysis of 10 protein biomarkers (A1AT, ANG, APOE, CA9, IL8, MMP9, MMP10, PAI1, SDC1 and VEGFA) by immunoassays, urine, diagnostic algorithm reported as a risk score for probability of rapid recurrence of recurrent or persistent cancer following transurethral resection	Investigational
<b>0369U</b>	Infectious agent detection by nucleic acid (DNA and RNA), gastrointestinal pathogens, 31 bacterial, viral, and parasitic organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique	Investigational
<b>0370U</b>	Infectious agent detection by nucleic acid (DNA and RNA), surgical wound pathogens, 34 microorganisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, wound swab	Investigational
<b>0371U</b>	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogen, semiquantitative identification, DNA from 16 bacterial organisms and 1 fungal organism, multiplex amplified probe technique via quantitative polymerase chain reaction (qPCR), urine	Investigational

<b>0372U</b>	Infectious disease (genitourinary pathogens), antibiotic-resistance gene detection, multiplex amplified probe technique, urine, reported as an antimicrobial stewardship risk score	Investigational
<b>0374U</b>	Infectious agent detection by nucleic acid (DNA or RNA), genitourinary pathogens, identification of 21 bacterial and fungal organisms and identification of 21 associated antibiotic-resistance genes, multiplex amplified probe technique, urine	Investigational
<b>0375U</b>	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	Investigational
<b>0376U</b>	Oncology (ovarian), biochemical assays of 7 proteins (follicle stimulating hormone, human epididymis protein 4, apolipoprotein A-1, transferrin, beta-2 macroglobulin, prealbumin [ie, transthyretin], and cancer antigen 125), algorithm reported as ovarian cancer risk score	Investigational
<b>0377U</b>	Cardiovascular disease, quantification of advanced serum or plasma lipoprotein profile, by nuclear magnetic resonance (NMR) spectrometry with report of a lipoprotein profile (including 23 variables)	Investigational
<b>0378U</b>	RFC1 (replication factor C subunit 1), repeat expansion variant analysis by traditional and repeat-primed PCR, blood, saliva, or buccal swab	Investigational

<b>0379U</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, DNA (523 genes) and RNA (55 genes) by next-generation sequencing, interrogation for sequence variants, gene copy number amplifications, gene rearrangements, microsatellite instability, and tumor mutational burden	Investigational
<b>0380U</b>	Drug metabolism (adverse drug reactions and drug response), targeted sequence analysis, 20 gene variants and CYP2D6 deletion or duplication analysis with reported genotype and phenotype	Investigational
<b>0384U</b>	Nephrology (chronic kidney disease), carboxymethyllysine, methylglyoxal hydroimidazolone, and carboxyethyl lysine by liquid chromatography with tandem mass spectrometry (LCMS/MS) and HbA1c and estimated glomerular filtration rate (GFR), with risk score reported for predictive progression to high-stage kidney disease	Investigational
<b>0385U</b>	Nephrology (chronic kidney disease), apolipoprotein A4 (ApoA4), CD5 antigen-like (CD5L), and insulin-like growth factor binding protein 3 (IGFBP3) by enzyme-linked immunoassay (ELISA), plasma, algorithm combining results with HDL, estimated glomerular filtration rate (GFR) and clinical data reported as a risk score for developing diabetic kidney disease	Investigational
<b>0387U</b>	Oncology (melanoma), autophagy and beclin 1 regulator 1 (AMBRA1) and loricrin (AMLo) by immunohistochemistry, formalin-fixed paraffin-embedded (FFPE) tissue, report for risk of progression	Investigational

<b>0389U</b>	Pediatric febrile illness (Kawasaki disease [KD]), interferon alpha-inducible protein 27 (IFI27) and mast cell-expressed membrane protein 1 (MCEMP1), RNA, using quantitative reverse transcription polymerase chain reaction (RT-qPCR), blood, reported as a risk score for KD	Investigational
<b>0390U</b>	Obstetrics (preeclampsia), kinase insert domain receptor (KDR), Endoglin (ENG), and retinol-binding protein 4 (RBP4), by immunoassay, serum, algorithm reported as a risk score	Investigational
<b>0391U</b>	"Oncology (solid tumor), DNA and RNA by next-generation sequencing, utilizing formalin-fixed paraffin-embedded (FFPE) tissue, 437 genes, interpretive report for single nucleotide variants, splice site variants, insertions/deletions, copy number alterations, gene fusions, tumor mutational burden, and microsatellite instability, with algorithm quantifying immunotherapy response score"	Investigational
<b>0392U</b>	"Drug metabolism (depression, anxiety, attention deficit hyperactivity disorder [ADHD]), gene-drug interactions, variant analysis of 16 genes, including deletion/duplication analysis of CYP2D6, reported as impact of gene-drug interaction for each drug"	Investigational

<p><b>0393U</b></p>	<p>SYNTap® Biomarker Test by Amprion Clinical Laboratory. The lab, this chemistry test aids in the diagnosis of synucleinopathies (e.g., Parkinson's disease, Lewy body dementia, multiple system atrophy (MSA), Lewy body variant of Alzheimer's disease) and differential diagnosis of other movement and cognitive disorders. A CSF specimen is subjected to qualitative seed amplification assay assessment for detection of misfolded aggregates of <math>\alpha</math>-synuclein protein</p>	<p>Investigational</p>
<p><b>0394U</b></p>	<p>PFAS Testing &amp; PFASure™, by National Medical Services (NMS Labs). Per the lab, this chemistry quantitative toxicology test, monitors for Perfluoroalkyl Substances, (eg. perfluorooctanoic acid, perfluorooctane sulfonic acid). Plasma or serum is analyzed by HPLC/Tandem Mass Spectrometry (LC-MS/MS) for 16 PFAS compounds and reported with a calculated NASEM Summation value (National Academies of Science, Engineering and Medicine guidance value). The US Department of Defense, Lab Corp (and other large national clinical laboratories) and individual State-Level agencies will order this testing in Serum/Plasma matrix to monitor for exposure to PFAS. NMS Labs anticipates that testing will begin in Q1 2023. Testing will be high volume.</p>	<p>Investigational</p>
<p><b>0395U</b></p>	<p>"Oncology (lung), multi-omics (microbial DNA by shotgun nextgeneration sequencing and carcinoembryonic antigen and osteopontin by immunoassay), plasma, algorithm reported as malignancy risk for lung nodules in early-stage disease"</p>	<p>Investigational</p>

<b>0397T</b>	Endoscopic retrograde cholangiopancreatography (ERCP), with optical endomicroscopy (List separately in addition to code for primary procedure)	Investigational
<b>0398U</b>	"Gastroenterology (Barrett esophagus), P16, RUNX3, HPP1, and FBN1 DNA methylation analysis using PCR, formalin-fixed paraffin-embedded (FFPE) tissue, algorithm reported as risk score for progression to high-grade dysplasia or cancer"	Investigational
<b>0399U</b>	Neurology (cerebral folate deficiency), serum, detection of anti-human folate receptor IgG binding antibody and blocking autoantibodies by enzyme-linked immunoassay (ELISA), qualitative, and blocking autoantibodies, using a functional blocking assay for IgG or IgM, quantitative, reported as positive or not detected	Investigational
<b>0400U</b>	Obstetrics (expanded carrier screening), 145 genes by next generation sequencing, fragment analysis and multiplex ligation dependent probe amplification, DNA, reported as carrier positive or negative	Investigational
<b>0401U</b>	Cardiology (coronary heart disease [-CHD]), 9 genes (12 variants), targeted variant genotyping, blood, saliva, or buccal swab, algorithm reported as a genetic risk score for a coronary event	Investigational
<b>0403U</b>	Oncology (prostate), mRNA, gene expression profiling of 18 genes, first-catch post-digital rectal examination urine (or processed first-catch urine), algorithm reported as percentage of likelihood of detecting clinically significant prostate cancer	Investigational
<b>0404U</b>	Oncology (breast), semiquantitative measurement of thymidine kinase activity by immunoassay, serum, results reported as risk of disease progression	Investigational



<b>0405U</b>	Oncology (pancreatic), 59 methylation haplotype block markers, next-generation sequencing, plasma, reported as cancer signal detected or not detected	Investigational
<b>0406U</b>	Oncology (lung), flow cytometry, sputum, 5 markers (meso-tetra [4-carboxyphenyl] porphyrin [TCPP], CD206, CD66b, CD3, CD19), algorithm reported as likelihood of lung cancer	Investigational
<b>0407U</b>	Nephrology (diabetic chronic kidney disease [CKD]), multiplex electrochemiluminescent immunoassay (ECLIA) of soluble tumor necrosis factor receptor 1 (sTNFR1), soluble tumor necrosis receptor 2 (sTNFR2), and kidney injury molecule 1 (KIM-1) combined with clinical data, plasma, algorithm reported as risk for progressive decline in kidney function	Investigational
<b>0408U</b>	Infectious agent antigen detection by bulk acoustic wave biosensor immunoassay, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19])	Investigational
<b>0410U</b>	Oncology (pancreatic), DNA, whole genome sequencing with 5-hydroxymethylcytosine enrichment, whole blood or plasma, algorithm reported as cancer detected or not detected	Investigational
<b>0411U</b>	Psychiatry (eg, depression, anxiety, attention deficit hyperactivity disorder [ADHD]), genomic analysis panel, variant analysis of 15 genes, including deletion/duplication analysis of CYP2D6 (For additional PLA code with identical clinical descriptor, see 0345U. See Appendix O to determine appropriate code assignment)	Investigational

<b>0412U</b>	Beta amyloid, AB42/40 ratio, immunoprecipitation with quantitation by liquid chromatography with tandem mass spectrometry (LC-MS/MS) and qualitative ApoE isoform-specific proteotyping, plasma combined with age, algorithm reported as presence or absence of brain amyloid pathology	Investigational
<b>0413U</b>	Oncology (hematolymphoid neoplasm), optical genome mapping for copy number alterations, aneuploidy, and balanced/complex structural rearrangements, DNA from blood or bone marrow, report of clinically significant alterations	Investigational
<b>0414U</b>	Oncology (lung), augmentative algorithmic analysis of digitized whole slide imaging for 8 genes (ALK, BRAF, EGFR, ERBB2, MET, NTRK1-3, RET, ROS1), and KRAS G12C and PD-L1, if performed, formalin-fixed paraffinembedded (FFPE) tissue, reported as positive or negative for each biomarker	Investigational
<b>0415U</b>	Cardiovascular disease (acute coronary syndrome [ACS]), IL-16, FAS, FASLigand, HGF, CTACK, EOTAXIN, and MCP-3 by immunoassay combined with age, sex, family history, and personal history of diabetes, blood, algorithm reported as a 5-year (deleted risk) score for ACS	Investigational
<b>0417U</b>	Rare diseases (constitutional/heritable disorders), whole mitochondrial genome sequence with heteroplasmy detection and deletion analysis, nuclearencoded mitochondrial gene analysis of 335 nuclear genes, including sequence changes, deletions, insertions, and copy number variants analysis, blood or saliva, identification and categorization of mitochondrial disorder-associated genetic variants	Investigational

<b>0418U</b>	Oncology (breast), augmentative algorithmic analysis of digitized whole slide imaging of 8 histologic and immunohistochemical features, reported as a recurrence score	Investigational
<b>0419U</b>	Neuropsychiatry (eg, depression, anxiety), genomic sequence analysis panel, variant analysis of 13 genes, saliva or buccal swab, report of each gene phenotype	Investigational
<b>0420U</b>	Oncology (bladder), mRNA expression profiling by real time quantitative PCR of 5 genes (MDK, HOXA13, CDC2, IGFBP5, and CXCR2) in combination with ddPCR analysis of 6 single nucleotide polymorphisms in two genes (TERT and FGFR3) utilizing a midstream voided urine sample, algorithm reported as a risk score of having urothelial carcinoma	Investigational
<b>0421U</b>	Oncology (colorectal) screening, quantitative real-time target and signal amplification of 8 RNA markers (GAPDH, SMAD4, ACY1, AREG, CDH1, KRAS, TNFRSF10B, and EGLN2) and fecal hemoglobin, utilizing stool, algorithm reported as a positive or negative result	Investigational
<b>0422U</b>	Oncology (pan-cancer), analysis of DNA biomarker response to anti-cancer therapy using cell-free circulating DNA, biomarker comparison to a previous baseline pre-treatment cell-free circulating DNA analysis using next-generation sequencing, algorithm reported as a quantitative change from baseline, including specific alterations, if appropriate	Investigational
<b>0423U</b>	Gene analysis panel for detection of variants in 26 genes associated with psychiatric and other pharmaceutical treatment (eg, depression, anxiety), genomic analysis panel, variant analysis of 26 genes	Investigational

<b>0424U</b>	Oncology (prostate) analysis of 53 small noncoding RNAs (sncRNAs), extracted from urinary exosomes, by quantitative real time polymerase chain reaction (rt-qPCR), reported as no molecular evidence, low-, moderate- or elevated-risk of prostate cancer	Investigational
<b>0427U</b>	Monocyte distribution width, whole blood (list separately in addition to code for primary procedure)	Investigational
<b>0429U</b>	Infectious disease (viral), real-time PCR testing for 14 high-risk HPV types using oropharyngeal swab	Investigational
<b>0430U</b>	Gastroenterology, malabsorption evaluation of alpha-1-antitrypsin, calprotectin, pancreatic elastase and reducing substances, feces, quantitative	Investigational
<b>0431U</b>	Glycine Receptor Alpha1 IgG, serum or cerebrospinal fluid (CSF), live Cell-Binding Assay (LCBA), qualitative	Investigational
<b>0432U</b>	Kelch-Like Protein 11 (KLHL11) Antibody, serum or cerebrospinal fluid (CSF), cell-binding assay, qualitative	Investigational
<b>0433U</b>	Oncology (prostate) 5 DNA regulatory markers by quantitative PCR, whole blood, algorithm, including prostate-specific antigen, reported as likelihood of cancer.	Investigational
<b>0434U</b>	Drug metabolism (adverse drug reactions and drug response), genomic analysis panel, variant analysis of 25 genes with reported phenotypes	Investigational
<b>0435U</b>	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on cytotoxicity percentage observed, minimum of 14 drugs or drug combinations	Investigational

<b>0436U</b>	Oncology (lung), plasma analysis of 388 proteins, using aptamer-based proteomics technology, predictive algorithm reported as clinical benefit from immune checkpoint inhibitor therapy.	Investigational
<b>0437U</b>	Psychiatry (anxiety disorders), mRNA gene expression profiling by RNA sequencing of 15 biomarkers, whole blood, algorithm reported as predictive risk score	Investigational
<b>0438U</b>	Drug Metabolism (adverse drug reactions and drug response) buccal specimen, gene-drug interactions, variant analysis of 33 genes, including deletion/duplication analysis of CYP2D6, including reported phenotypes and impacted gene-drug interactions	Investigational
<b>0439U</b>	Cardiology (coronary heart disease [CHD]), DNA analysis of 5 single-nucleotide polymorphisms (SNPs) (rs11716050 [LOC105376934], rs6560711 [WDR37], rs3735222 [SCIN/LOC107986769], rs6820447 [intergenic], and rs9638144 [ESYT2]) and 3 DNA methylation markers (cg00300879 [transcription start site {TSS200} of CNKSR1], cg09552548 [intergenic], and cg14789911 [body of SPATC1L]), qPCR and digital PCR, whole blood, algorithm reported as a 4-tiered risk score for a 3-year risk of symptomatic CHD	Investigational

<b>0440U</b>	Cardiology (coronary heart disease [CHD]), DNA, analysis of 10 single-nucleotide polymorphisms (SNPs) (rs710987 [LINC010019], rs1333048 [CDKN2B-AS1], rs12129789 [KCND3], rs942317 [KTN1-AS1], rs1441433 [PPP3CA], rs2869675 [PREX1], rs4639796 [ZBTB41], rs4376434 [LINC00972], rs12714414 [TMEM18], and rs7585056 [TMEM18]) and 6 DNA methylation markers (cg03725309 [SARS1], cg12586707 [CXCL1, cg04988978 [MPO], cg17901584 [DHCR24-DT], cg21161138 [AHRR], and cg12655112 [EHD4]), qPCR and digital PCR, whole blood, algorithm reported as detected or not detected for CHD	Investigational
<b>0441U</b>	Infectious disease (bacterial, fungal or viral infection), semiquantitative biomechanical assessment (via deformability cytometry), whole blood, with algorithmic analysis and result reported as an index.	Investigational
<b>0442U</b>	Infectious disease (respiratory infection), Myxovirus resistance protein A (MxA) and C-reactive protein (CRP), fingerstick whole blood specimen, each biomarker reported as present or absent	Investigational
<b>0443U</b>	Neurofilament light chain (NfL), ultra-sensitive immunoassay , serum or cerebrospinal fluid	Investigational
<b>0444U</b>	Oncology (solid organ neoplasia), targeted genomic sequence panel of 361 genes, interrogation for gene fusions, translocations, or other rearrangements, using DNA from formalin-fixed paraffin-embedded (DDPE) tumor tissue, report of clinically significant variant(s)	Investigational
<b>0445U</b>	Bamyloid (Abeta42) and Phospho Tau (181P) (pTau181), electrochemiluminescence immunoassay (ECLIA), cerebral spinal fluid, ratio reported as positive or negative for amyloid pathology	Investigational

<b>0446U</b>	Autoimmune diseases (systemic lupus erythematosus) [SLE], analysis of 10 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic risk score for current disease activity	Investigational
<b>0447U</b>	Autoimmune diseases (systemic lupus erythematosus [SLE]), analysis of 11 cytokine soluble mediator biomarkers by immunoassay, plasma, individual components reported with an algorithmic prognostic risk score for developing a clinical flare	Investigational
<b>0449U</b>	Carrier screening for severe inherited conditions (eg, cystic fibrosis, spinal muscular atrophy, beta hemoglobinopathies [including sickle cell disease], alpha thalassemias) regardless of race or self-identified ancestry, genomic sequence analysis of 5 genes (CFTR, SMN1, HBB, HBA1, HBA2)	Investigational
<b>0441T</b>	Ablation, percutaneous, cryoablation, includes imaging guidance; lower extremity distal/peripheral nerve	Investigational
<b>0450U</b>	Oncology (multiple myeloma), liquid chromatography with tandem mass spectrometry (LC-MS/MS), monoclonal paraprotein sequencing analysis, serum, results reported as baseline presence or absence of detectable clonotypic peptides	Investigational
<b>0451U</b>	Oncology (multiple myeloma), LC-MS/MS, peptide ion quantification, serum, results compared with baseline to determine monoclonal paraprotein abundance	Investigational
<b>0452U</b>	Oncology (bladder), methylated PENK DNA detection by linear target enrichment-quantitative methylation-specific real-time PCR (LTE-qMSP), urine, reported as likelihood of bladder cancer	Investigational

<b>0453U</b>	Oncology (colorectal cancer), cell-free DNA (cfDNA), methylation-based quantitative PCR assay (SEPTIN9, IKZF1, BCAT1, Septin9-2, VAV3, BCAN), plasma, reported as presence or absence of circulating tumor DNA (ctDNA)	Investigational
<b>0456U</b>	Autoimmune (rheumatoid arthritis), next-generation sequencing (NGS), gene expression testing of 19 genes, whole blood, with analysis of anti-cyclic citrullinated peptides (CCP) levels, combined with sex, patient global assessment, and body mass index (BMI), algorithm reported as a score that predicts nonresponse to tumor necrosis factor inhibitor (TNFi) therapy	Investigational
<b>0457U</b>	Perfluoroalkyl substances (PFAS) (eg, perfluorooctanoic acid, perfluorooctane sulfonic acid), 9 PFAS compounds by LC-MS/MS, plasma or serum, quantitative	Investigational
<b>0458U</b>	Oncology (breast cancer), S100A8 and S100A9, by enzyme-linked immunosorbent assay (ELISA), tear fluid with age, algorithm reported as a risk score	Investigational
<b>0460U</b>	Oncology, whole blood or buccal, DNA single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, with variant analysis and reported phenotypes	Investigational
<b>0461U</b>	Oncology, pharmacogenomic analysis of single-nucleotide polymorphism (SNP) genotyping by real-time PCR of 24 genes, whole blood or buccal swab, with variant analysis, including impacted gene-drug interactions and reported phenotypes	Investigational
<b>0462U</b>	Melatonin levels test, sleep study, 7 or 9 sample melatonin profile (cortisol optional), enzyme-linked immunosorbent assay (ELISA), saliva, screening/preliminary	Investigational



<b>0463U</b>	Oncology (cervix), mRNA gene expression profiling of 14 biomarkers (E6 and E7 of the highest-risk human papillomavirus [HPV] types 16, 18, 31, 33, 45, 52, 58), by real-time nucleic acid sequence-based amplification (NASBA), exo- or endocervical epithelial cells, algorithm reported as positive or negative for increased risk of cervical dysplasia or cancer for each biomarker	Investigational
<b>0464U</b>	Oncology (colorectal) screening, quantitative real-time target and signal amplification, methylated DNA markers, including LASS4, LRRC4 and PPP2R5C, a reference marker ZDHHC1, and a protein marker (fecal hemoglobin), utilizing stool, algorithm reported as a positive or negative result	Investigational
<b>0465U</b>	Oncology (urothelial carcinoma), DNA, quantitative methylation-specific PCR of 2 genes (ONECUT2, VIM), algorithmic analysis reported as positive or negative	Investigational
<b>0466U</b>	Cardiology (coronary artery disease [CAD]), DNA, genome-wide association studies (564856 single-nucleotide polymorphisms [SNPs], targeted variant genotyping), patient lifestyle and clinical data, buccal swab, algorithm reported as polygenic risk to acquired heart disease	Investigational
<b>0467U</b>	Oncology (bladder), DNA, next-generation sequencing (NGS) of 60 genes and whole genome aneuploidy, urine, algorithms reported as minimal residual disease (MRD) status positive or negative and quantitative disease burden	Investigational

<b>0468U</b>	Hepatology (nonalcoholic steatohepatitis [NASH]), miR-34a-5p, alpha 2-macroglobulin, YKL40, HbA1c, serum and whole blood, algorithm reported as a single score for NASH activity and fibrosis	Investigational
<b>0469U</b>	Rare diseases (constitutional/heritable disorders), whole genome sequence analysis for chromosomal abnormalities, copy number variants, duplications/deletions, inversions, unbalanced translocations, regions of homozygosity (ROH), inheritance pattern that indicate uniparental disomy (UPD), and aneuploidy, fetal sample (amniotic fluid, chorionic villus sample, or products of conception), identification and categorization of genetic variants, diagnostic report of fetal results based on phenotype with maternal sample and paternal sample, if performed, as comparators and/or maternal cell contamination	Investigational
<b>0470U</b>	Oncology (oropharyngeal), detection of minimal residual disease by next-generation sequencing (NGS) based quantitative evaluation of 8 DNA targets, cell-free HPV 16 and 18 DNA from plasma	Investigational
<b>0472U</b>	Carbonic anhydrase VI (CA VI), parotid specific/secretory protein (PSP) and salivary protein (SP1) IgG, IgM, and IgA antibodies, enzyme-linked immunosorbent assay (ELISA), semiquantitative, blood, reported as predictive evidence of early Sjogren syndrome	Investigational

<b>0474U</b>	Hereditary pan-cancer (eg, hereditary sarcomas, hereditary endocrine tumors, hereditary neuroendocrine tumors, hereditary cutaneous melanoma), genomic sequence analysis panel of 88 genes with 20 duplications/deletions using next-generation sequencing (NGS), Sanger sequencing, blood or saliva, reported as positive or negative for germline variants, each gene	Investigational
<b>0475U</b>	Hereditary prostate cancer-related disorders, genomic sequence analysis panel using next-generation sequencing (NGS), Sanger sequencing, multiplex ligation-dependent probe amplification (MLPA), and array comparative genomic hybridization (CGH), evaluation of 23 genes and duplications/deletions when indicated, pathologic mutations reported with a genetic risk score for prostate cancer	Investigational
<b>0506T</b>	Macular pigment optical density measurement by heterochromatic flicker photometry, unilateral or bilateral, with interpretation and report	Investigational
<b>0507T</b>	Near-infrared dual imaging (ie, simultaneous reflective and trans-illuminated light) of meibomian glands, unilateral or bilateral, with interpretation and report	Investigational
<b>0509T</b>	Electroretinography (ERG) with interpretation and report, pattern (PERG)	Investigational
<b>0510T</b>	Removal of sinus tarsi implant	Investigational
<b>0511T</b>	Removal and reinsertion of sinus tarsi implant	Investigational
<b>0512T</b>	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; initial wound	Investigational

<b>0513T</b>	Extracorporeal shock wave for integumentary wound healing, including topical application and dressing care; each additional wound (List separately in addition to code for primary procedure)	Investigational
<b>0515T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; complete system (includes electrode and generator [transmitter and battery])	Investigational
<b>0516T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; electrode only	Investigational
<b>0517T</b>	Insertion of wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming, and imaging supervision and interpretation, when performed; both components of pulse generator (battery and transmitter) only	Investigational
<b>0518T</b>	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; battery component only	Investigational
<b>0519T</b>	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; both components (battery and transmitter)	Investigational
<b>0520T</b>	Removal and replacement of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only	Investigational

<b>0521T</b>	Interrogation device evaluation (in person) with analysis, review and report, includes connection, recording, and disconnection per patient encounter, wireless cardiac stimulator for left ventricular pacing	Investigational
<b>0522T</b>	Programming device evaluation (in person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, including review and report, wireless cardiac stimulator for left ventricular pacing	Investigational
<b>0523T</b>	Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time review and interpretation of possible atherosclerotic stenosis(es) intervention (List separately in addition to code for primary procedure)	Investigational
<b>0524T</b>	Endovenous catheter directed chemical ablation with balloon isolation of incompetent extremity vein, open or percutaneous, including all vascular access, catheter manipulation, diagnostic imaging, imaging guidance and monitoring	Investigational
<b>0525T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational

<b>0526T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; electrode only	Investigational
<b>0527T</b>	Insertion or replacement of intracardiac ischemia monitoring system, including testing of the lead and monitor, initial system programming, and imaging supervision and interpretation; implantable monitor only	Investigational
<b>0528T</b>	Programming device evaluation (in person) of intracardiac ischemia monitoring system with iterative adjustment of programmed values, with analysis, review, and report	Investigational
<b>0529T</b>	Interrogation device evaluation (in person) of intracardiac ischemia monitoring system with analysis, review, and report	Investigational
<b>0530T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; complete system (electrode and implantable monitor)	Investigational
<b>0531T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; electrode only	Investigational
<b>0532T</b>	Removal of intracardiac ischemia monitoring system, including all imaging supervision and interpretation; implantable monitor only	Investigational
<b>0541T</b>	Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study;	Investigational

<b>0542T</b>	Myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images, quantitative analysis of magnetic dipoles, machine learning-derived clinical scoring, and automated report generation, single study; interpretation and report	Investigational
<b>0543T</b>	Transapical mitral valve repair, including transthoracic echocardiography, when performed, with placement of artificial chordae tendineae	Investigational
<b>0545T</b>	Transcatheter tricuspid valve annulus reconstruction with implantation of adjustable annulus reconstruction device, percutaneous approach	Investigational
<b>0546T</b>	Radiofrequency spectroscopy, real time, intraoperative margin assessment, at the time of partial mastectomy, with report	Investigational
<b>0547T</b>	Bone-material quality testing by microindentation(s) of the tibia(s), with results reported as a score	Investigational
<b>0553T</b>	Percutaneous transcatheter placement of iliac arteriovenous anastomosis implant, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention	Investigational
<b>0554T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data, assessment of bone strength and fracture risk and bone mineral density, interpretation and report	Investigational

<b>0555T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; retrieval and transmission of the scan data	Investigational
<b>0556T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; assessment of bone strength and fracture risk and bone mineral density	Investigational
<b>0557T</b>	Bone strength and fracture risk using finite element analysis of functional data, and bone-mineral density, utilizing data from a computed tomography scan; interpretation and report	Investigational
<b>0558T</b>	Computed tomography scan taken for the purpose of biomechanical computed tomography analysis	Investigational
<b>0559T</b>	Anatomic model 3D-printed from image data set(s); first individually prepared and processed component of an anatomic structure	Investigational
<b>0560T</b>	Anatomic model 3D-printed from image data set(s); each additional individually prepared and processed component of an anatomic structure (List separately in addition to code for primary procedure)	Investigational
<b>0561T</b>	Anatomic guide 3D-printed and designed from image data set(s); first anatomic guide	Investigational
<b>0562T</b>	Anatomic guide 3D-printed and designed from image data set(s); each additional anatomic guide (List separately in addition to code for primary procedure)	Investigational
<b>0563T</b>	Evacuation of meibomian glands, using heat delivered through wearable, open-eye eyelid treatment devices and manual gland expression, bilateral	Investigational



<b>0564T</b>	Oncology, chemotherapeutic drug cytotoxicity assay of cancer stem cells (CSCs), from cultured CSCs and primary tumor cells, categorical drug response reported based on percent of cytotoxicity observed, a minimum of 14 drugs or drug combinations	Investigational
<b>0565T</b>	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; tissue harvesting and cellular implant creation	Investigational
<b>0566T</b>	Autologous cellular implant derived from adipose tissue for the treatment of osteoarthritis of the knees; injection of cellular implant into knee joint including ultrasound guidance, unilateral	Investigational
<b>0567T</b>	Permanent fallopian tube occlusion with degradable biopolymer implant, transcervical approach, including transvaginal ultrasound	Investigational
<b>0568T</b>	Introduction of mixture of saline and air for sonosalpingography to confirm occlusion of fallopian tubes, transcervical approach, including transvaginal ultrasound and pelvic ultrasound	Investigational
<b>0569T</b>	Transcatheter tricuspid valve repair, percutaneous approach; initial prosthesis	Investigational
<b>0570T</b>	Transcatheter tricuspid valve repair, percutaneous approach; each additional prosthesis during same session (List separately in addition to code for primary procedure)	Investigational
<b>0581T</b>	Ablation, malignant breast tumor(s), percutaneous, cryotherapy, including imaging guidance when performed, unilateral	Investigational
<b>0582T</b>	Transurethral ablation of malignant prostate tissue by high-energy water vapor thermotherapy, including intraoperative imaging and needle guidance	Investigational

<b>0583T</b>	Tympanostomy (requiring insertion of ventilating tube), using an automated tube delivery system, iontophoresis local anesthesia	Investigational
<b>0587T</b>	Percutaneous implantation or replacement of integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational
<b>0588T</b>	Revision or removal of percutaneously placed integrated single device neurostimulation system for bladder dysfunction including electrode array and receiver or pulse generator, including analysis, programming, and imaging guidance when performed, posterior tibial nerve	Investigational
<b>0589T</b>	Electronic analysis with simple programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 1-3 parameters	Investigational

<b>0590T</b>	Electronic analysis with complex programming of implanted integrated neurostimulation system for bladder dysfunction (eg, electrode array and receiver), including contact group(s), amplitude, pulse width, frequency (Hz), on/off cycling, burst, dose lockout, patient-selectable parameters, responsive neurostimulation, detection algorithms, closed-loop parameters, and passive parameters, when performed by physician or other qualified health care professional, posterior tibial nerve, 4 or more parameters	Investigational
<b>0594T</b>	Osteotomy, humerus, with insertion of an externally controlled intramedullary lengthening device, including intraoperative imaging, initial and subsequent alignment assessments, computations of adjustment schedules, and management of the intramedullary lengthening device	Investigational
<b>0596T</b>	Temporary female intraurethral valve-pump (ie, voiding prosthesis); initial insertion, including urethral measurement	Investigational
<b>0597T</b>	Temporary female intraurethral valve-pump (ie, voiding prosthesis); replacement	Investigational
<b>0598T</b>	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (eg, lower extremity)	Investigational
<b>0599T</b>	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (eg, upper extremity) (List separately in addition to code for primary procedure)	Investigational

<b>0602T</b>	Glomerular filtration rate (GFR) measurement(s), transdermal, including sensor placement and administration of a single dose of fluorescent pyrazine agent	Investigational
<b>0603T</b>	Glomerular filtration rate (GFR) monitoring, transdermal, including sensor placement and administration of more than one dose of fluorescent pyrazine agent, each 24 hours	Investigational
<b>0604T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; initial device provision, set-up and patient education on use of equipment	Investigational
<b>0605T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; remote surveillance center technical support, data analyses and reports, with a minimum of 8 daily recordings, each 30 days	Investigational
<b>0606T</b>	Optical coherence tomography (OCT) of retina, remote, patient-initiated image capture and transmission to a remote surveillance center unilateral or bilateral; review, interpretation and report by the prescribing physician or other qualified health care professional of remote surveillance center data analyses, each 30 days	Investigational
<b>0607T</b>	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; set-up and patient education on use of equipment	Investigational

<b>0608T</b>	Remote monitoring of an external continuous pulmonary fluid monitoring system, including measurement of radiofrequency-derived pulmonary fluid levels, heart rate, respiration rate, activity, posture, and cardiovascular rhythm (eg, ECG data), transmitted to a remote 24-hour attended surveillance center; analysis of data received and transmission of reports to the physician or other qualified health care professional	Investigational
<b>0609T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); acquisition of single voxel data, per disc, on biomarkers (ie, lactic acid, carbohydrate, alanine, laal, propionic acid, proteoglycan, and collagen) in at least 3 discs	Investigational
<b>0610T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); transmission of biomarker data for software analysis	Investigational
<b>0611T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); postprocessing for algorithmic analysis of biomarker data for determination of relative chemical differences between discs	Investigational
<b>0612T</b>	Magnetic resonance spectroscopy, determination and localization of discogenic pain (cervical, thoracic, or lumbar); interpretation and report	Investigational
<b>0613T</b>	Percutaneous transcatheter implantation of interatrial septal shunt device, including right and left heart catheterization, intracardiac echocardiography, and imaging guidance by the proceduralist, when performed	Investigational

<b>0614T</b>	Removal and replacement of substernal implantable defibrillator pulse generator	Investigational
<b>0615T</b>	Eye-movement analysis without spatial calibration, with interpretation and report	Investigational
<b>0619T</b>	Cystourethroscopy with transurethral anterior prostate commissurotomy and drug delivery, including transrectal ultrasound and fluoroscopy, when performed	Investigational
<b>0620T</b>	Endovascular venous arterialization, tibial or peroneal vein, with transcatheter placement of intravascular stent graft(s) and closure by any method, including percutaneous or open vascular access, ultrasound guidance for vascular access when performed, all catheterization(s) and intraprocedural roadmapping and imaging guidance necessary to complete the intervention, all associated radiological supervision and interpretation, when performed	Investigational
<b>0621T</b>	Trabeculostomy ab interno by laser	Investigational
<b>0622T</b>	Trabeculostomy ab interno by laser; with use of ophthalmic endoscope	Investigational
<b>0623T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission, computerized analysis of data, with review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational
<b>0624T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; data preparation and transmission	Investigational

<b>0625T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; computerized analysis of data from coronary computed tomographic angiography	Investigational
<b>0626T</b>	Automated quantification and characterization of coronary atherosclerotic plaque to assess severity of coronary disease, using data from coronary computed tomographic angiography; review of computerized analysis output to reconcile discordant data, interpretation and report	Investigational
<b>0627T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; first level	Investigational
<b>0628T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with fluoroscopic guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
<b>0629T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; first level	Investigational
<b>0630T</b>	Percutaneous injection of allogeneic cellular and/or tissue-based product, intervertebral disc, unilateral or bilateral injection, with CT guidance, lumbar; each additional level (List separately in addition to code for primary procedure)	Investigational
<b>0631T</b>	Transcutaneous visible light hyperspectral imaging measurement of oxyhemoglobin, deoxyhemoglobin, and tissue oxygenation, with interpretation and report, per extremity	Investigational

<b>0632T</b>	Percutaneous transcatheter ultrasound ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational
<b>0633T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast material	Investigational
<b>0634T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; with contrast material(s)	Investigational
<b>0635T</b>	Computed tomography, breast, including 3D rendering, when performed, unilateral; without contrast, followed by contrast material(s)	Investigational
<b>0636T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast material(s)	Investigational
<b>0637T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; with contrast material(s)	Investigational
<b>0638T</b>	Computed tomography, breast, including 3D rendering, when performed, bilateral; without contrast, followed by contrast material(s)	Investigational
<b>0639T</b>	Wireless skin sensor thermal anisotropy measurement(s) and assessment of flow in cerebrospinal fluid shunt, including ultrasound guidance, when performed	Investigational
<b>0640T</b>	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; first anatomic site	Investigational



<b>0643T</b>	Transcatheter left ventricular restoration device implantation including right and left heart catheterization and left ventriculography when performed, arterial approach	Investigational
<b>0646T</b>	Transcatheter tricuspid valve implantation (TTVI)/replacement with prosthetic valve, percutaneous approach, including right heart catheterization, temporary pacemaker insertion, and selective right ventricular or right atrial angiography, when performed	Investigational
<b>0647T</b>	Insertion of gastrostomy tube, percutaneous, with magnetic gastropexy, under ultrasound guidance, image documentation and report	Investigational
<b>0651T</b>	Magnetically controlled capsule endoscopy, esophagus through stomach, including intraprocedural positioning of capsule, with interpretation and report	Investigational
<b>0652T</b>	Esophagogastroduodenoscopy, flexible, transnasal; diagnostic, including collection of specimen(s) by brushing or washing, when performed (separate procedure)	Investigational
<b>0653T</b>	Esophagogastroduodenoscopy, flexible, transnasal; with biopsy, single or multiple	Investigational
<b>0654T</b>	Esophagogastroduodenoscopy, flexible, transnasal; with insertion of intraluminal tube or catheter	Investigational
<b>0655T</b>	Transperineal focal laser ablation of malignant prostate tissue, including transrectal imaging guidance, with MR-fused images or other enhanced ultrasound imaging	Investigational
<b>0656T</b>	Anterior lumbar or thoracolumbar vertebral body tethering; up to 7 vertebral segments	Investigational

<b>0657T</b>	Anterior lumbar or thoracolumbar vertebral body tethering; 8 or more vertebral segments	Investigational
<b>0658T</b>	Electrical impedance spectroscopy of 1 or more skin lesions for automated melanoma risk score	Investigational
<b>0659T</b>	Transcatheter intracoronary infusion of supersaturated oxygen in conjunction with percutaneous coronary revascularization during acute myocardial infarction, including catheter placement, imaging guidance (eg, fluoroscopy), angiography, and radiologic supervision and interpretation	Investigational
<b>0660T</b>	Implantation of anterior segment intraocular nonbiodegradable drug-eluting system, internal approach	Investigational
<b>0661T</b>	Removal and reimplantation of anterior segment intraocular nonbiodegradable drug-eluting implant	Investigational
<b>0664T</b>	Donor hysterectomy (including cold preservation); open, from cadaver donor	Investigational
<b>0665T</b>	Donor hysterectomy (including cold preservation); open, from living donor	Investigational
<b>0666T</b>	Donor hysterectomy (including cold preservation); laparoscopic or robotic, from living donor	Investigational
<b>0667T</b>	Donor hysterectomy (including cold preservation); recipient uterus allograft transplantation from cadaver or living donor	Investigational
<b>0668T</b>	Backbench standard preparation of cadaver or living donor uterine allograft prior to transplantation, including dissection and removal of surrounding soft tissues and preparation of uterine vein(s) and uterine artery(ies), as necessary	Investigational
<b>0669T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; venous anastomosis, each	Investigational

<b>0670T</b>	Backbench reconstruction of cadaver or living donor uterus allograft prior to transplantation; arterial anastomosis, each	Investigational
<b>0672T</b>	Endovaginal cryogen-cooled, monopolar radiofrequency remodeling of the tissues surrounding the female bladder neck and proximal urethra for urinary incontinence	Investigational
<b>0673T</b>	Ablation, benign thyroid nodule(s), percutaneous, laser, including imaging guidance	Investigational
<b>0674T</b>	Laparoscopic insertion of new or replacement of permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including an implantable pulse generator and diaphragmatic lead(s)	Investigational
<b>0675T</b>	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first lead	Investigational
<b>0676T</b>	Laparoscopic insertion of new or replacement of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional lead (List separately in addition to code for primary procedure)	Investigational
<b>0677T</b>	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; first repositioned lead	Investigational

<b>0678T</b>	Laparoscopic repositioning of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, including connection to an existing pulse generator; each additional repositioned lead (List separately in addition to code for primary procedure)	Investigational
<b>0679T</b>	Laparoscopic removal of diaphragmatic lead(s), permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0680T</b>	Insertion or replacement of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing lead(s)	Investigational
<b>0681T</b>	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational
<b>0682T</b>	Relocation of pulse generator only, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function, with connection to existing dual leads	Investigational

<b>0683T</b>	Programming device evaluation (in-person) with iterative adjustment of the implantable device to test the function of the device and select optimal permanent programmed values with analysis, review and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0684T</b>	Peri-procedural device evaluation (in-person) and programming of device system parameters before or after a surgery, procedure, or test with analysis, review, and report by a physician or other qualified health care professional, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0685T</b>	Interrogation device evaluation (in-person) with analysis, review and report by a physician or other qualified health care professional, including connection, recording and disconnection per patient encounter, permanent implantable synchronized diaphragmatic stimulation system for augmentation of cardiac function	Investigational
<b>0686T</b>	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant hepatocellular tissue, including image guidance	Investigational
<b>0687T</b>	Treatment of amblyopia using an online digital program; device supply, educational set-up, and initial session	Investigational

<b>0688T</b>	Treatment of amblyopia using an online digital program; assessment of patient performance and program data by physician or other qualified health care professional, with report, per calendar month	Investigational
<b>0689T</b>	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained without diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure)	Investigational
<b>0690T</b>	Quantitative ultrasound tissue characterization (non-elastographic), including interpretation and report, obtained with diagnostic ultrasound examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	Investigational
<b>0691T</b>	Automated analysis of an existing computed tomography study for vertebral fracture(s), including assessment of bone density when performed, data preparation, interpretation, and report	Investigational
<b>0693T</b>	Comprehensive full body computer-based markerless 3D kinematic and kinetic motion analysis and report	Investigational
<b>0694T</b>	3-dimensional volumetric imaging and reconstruction of breast or axillary lymph node tissue, each excised specimen, 3-dimensional automatic specimen reorientation, interpretation and report, real-time intraoperative	Investigational

<b>0695T</b>	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of implant or replacement	Investigational
<b>0696T</b>	Body surface-activation mapping of pacemaker or pacing cardioverter-defibrillator lead(s) to optimize electrical synchrony, cardiac resynchronization therapy device, including connection, recording, disconnection, review, and report; at time of follow-up interrogation or programming device evaluation	Investigational
<b>0697T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session; multiple organs	Investigational
<b>0698T</b>	Quantitative magnetic resonance for analysis of tissue composition (eg, fat, iron, water content), including multiparametric data acquisition, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the same anatomy (eg, organ, gland, tissue, target structure); multiple organs (List separately in addition to code for primary procedure)	Investigational
<b>0700T</b>	Molecular fluorescent imaging of suspicious nevus; first lesion	Investigational
<b>0701T</b>	Molecular fluorescent imaging of suspicious nevus; each additional lesion (List separately in addition to code for primary procedure)	Investigational

<b>0704T</b>	Remote treatment of amblyopia using an eye tracking device; device supply with initial set-up and patient education on use of equipment	Investigational
<b>0705T</b>	Remote treatment of amblyopia using an eye tracking device; surveillance center technical support including data transmission with analysis, with a minimum of 18 training hours, each 30 days	Investigational
<b>0706T</b>	Remote treatment of amblyopia using an eye tracking device; interpretation and report by physician or other qualified health care professional, per calendar month	Investigational
<b>0707T</b>	Injection(s), bone substitute material (eg, calcium phosphate) into subchondral bone defect (ie, bone marrow lesion, bone bruise, stress injury, microtrabecular fracture), including imaging guidance and arthroscopic assistance for joint visualization	Investigational
<b>0708T</b>	Intradermal cancer immunotherapy; preparation and initial injection	Investigational
<b>0709T</b>	Intradermal cancer immunotherapy; each additional injection (List separately in addition to code for primary procedure)	Investigational
<b>0710T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; including data preparation and transmission, quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability, data review, interpretation and report	Investigational
<b>0711T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data preparation and transmission	Investigational



<b>0712T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; quantification of the structure and composition of the vessel wall and assessment for lipid-rich necrotic core plaque to assess atherosclerotic plaque stability	Investigational
<b>0713T</b>	Noninvasive arterial plaque analysis using software processing of data from non-coronary computerized tomography angiography; data review, interpretation and report	Investigational
<b>0714T</b>	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume less than 50 mL	Investigational
<b>0716T</b>	Cardiac acoustic waveform recording with automated analysis and generation of coronary artery disease risk score	Investigational
<b>0717T</b>	"Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; adipose tissue harvesting, isolation and preparation of harvested cells, including incubation with cell dissociation enzymes, filtration, washing and concentration of ADRCs	Investigational
<b>0718T</b>	Autologous adipose-derived regenerative cell (ADRC) therapy for partial thickness rotator cuff tear; injection into supraspinatus tendon including ultrasound guidance, unilateral	Investigational
<b>0719T</b>	Posterior vertebral joint replacement, including bilateral facetectomy, laminectomy, and radical discectomy, including imaging guidance, lumbar spine, single segment	Investigational
<b>0720T</b>	Percutaneous electrical nerve field stimulation, cranial nerves, without implantation	Investigational

<b>0721T</b>	Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging	Investigational
<b>0722T</b>	Quantitative computed tomography (CT) tissue characterization, including interpretation and report, obtained with concurrent CT examination of any structure contained in the concurrently acquired diagnostic imaging dataset (List separately in addition to code for primary procedure)	Investigational
<b>0723T</b>	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained without diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) during the same session	Investigational
<b>0724T</b>	Quantitative magnetic resonance cholangiopancreatography (QMRCP) including data preparation and transmission, interpretation and report, obtained with diagnostic magnetic resonance imaging (MRI) examination of the same anatomy (eg, organ, gland, tissue, target structure) (List separately in addition to code for primary procedure)	Investigational
<b>0725T</b>	Vestibular device implantation, unilateral	Investigational
<b>0726T</b>	Removal of implanted vestibular device, unilateral	Investigational
<b>0727T</b>	Removal and replacement of implanted vestibular device, unilateral	Investigational

<b>0728T</b>	Diagnostic analysis of vestibular implant, unilateral; with initial programming	Investigational
<b>0729T</b>	with subsequent programming (For initial and subsequent diagnostic analysis and programming of cochlear implant	Investigational
<b>0730T</b>	Trabeculotomy by laser, including optical coherence tomography (OCT) guidance	Investigational
<b>0731T</b>	Augmentative AI-based facial phenotype analysis with report	Investigational
<b>0732T</b>	Immunotherapy administration with electroporation, intramuscular	Investigational
<b>0733T</b>	Remote therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days	Investigational
<b>0734T</b>	Remote body and limb kinematic measurement-based therapy ordered by a physician or other qualified health care professional; supply and technical support, per 30 days; treatment management services by a physician or other qualified health care professional, per calendar month"	Investigational
<b>0735T</b>	"Preparation of tumor cavity, with placement of a radiation therapy applicator for intraoperative radiation therapy (IORT) concurrent with primary craniotomy (List separately in addition to code for primary procedure)	Investigational
<b>0736T</b>	Colonic lavage, 35 or more liters of water, gravity-fed, with induced defecation, including insertion of rectal catheter	Investigational
<b>0737T</b>	Xenograft implantation into the articular surface	Investigational
<b>0738T</b>	Treatment planning for magnetic field induction ablation of malignant prostate tissue, using data from previously performed magnetic resonance imaging (MRI) examination	Investigational

<b>0739T</b>	Ablation of malignant prostate tissue by magnetic field induction, including all intraprocedural, transperineal needle/catheter placement for nanoparticle installation and intraprocedural temperature monitoring, thermal dosimetry, bladder irrigation, and magnetic field nanoparticle activation	Investigational
<b>0740T</b>	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education	Investigational
<b>0741T</b>	Remote autonomous algorithm-based recommendation system for insulin dose calculation and titration; initial set-up and patient education; provision of software, data collection, transmission, and storage, each 30 days	Investigational
<b>0742T</b>	Absolute quantitation of myocardial blood flow (AQMBF), single-photon emission computed tomography (SPECT), with exercise or pharmacologic stress, and at rest, when performed (List separately in addition to code for primary procedure)	Investigational
<b>0743T</b>	Bone strength and fracture risk using finite element analysis of functional data and bone-mineral density, with concurrent vertebral fracture assessment, utilizing data from a computed tomography scan, retrieval and transmission of the scan data, measurement of bone strength and bone mineral density and classification of any vertebral fractures, with overall fracture risk assessment, interpretation and report	Investigational

<b>0744T</b>	Insertion of bioprosthetic valve, open, femoral vein, including duplex ultrasound imaging guidance, when performed, including autogenous or nonautogenous patch graft (eg, polyester, ePTFE, bovine pericardium), when performed	Investigational
<b>0745T</b>	Cardiac focal ablation utilizing radiation therapy for arrhythmia; noninvasive arrhythmia localization and mapping of arrhythmia site (nidus), derived from anatomical image data (eg, CT, MRI, or myocardial perfusion scan) and electrical data (eg, 12-lead ECG data), and identification of areas of avoidance	Investigational
<b>0746T</b>	Cardiac focal ablation utilizing radiation therapy for arrhythmia; conversion of arrhythmia localization and mapping of arrhythmia site (nidus) into a multidimensional radiation treatment plan	Investigational
<b>0747T</b>	Cardiac focal ablation utilizing radiation therapy for arrhythmia; delivery of radiation therapy, arrhythmia	Investigational
<b>0748T</b>	Injections of stem cell product into perianal perifistular soft tissue, including fistula preparation (eg, removal of setons, fistula curettage, closure of internal openings)	Investigational
<b>0749T</b>	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report	Investigational

<b>0750T</b>	Bone strength and fracture-risk assessment using digital X-ray radiogrammetrybone mineral density (DXR-BMD) analysis of bone mineral density (BMD) utilizing data from a digital X ray, retrieval and transmission of digital X ray data, assessment of bone strength and fracture-risk and BMD, interpretation and report; with single-view digital X-ray examination of the hand taken for the purpose of DXR-BMD	Investigational
<b>0751T</b>	Digitization of glass microscope slides for level II, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
<b>0752T</b>	Digitization of glass microscope slides for level III, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
<b>0753T</b>	Digitization of glass microscope slides for level IV, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
<b>0754T</b>	Digitization of glass microscope slides for level V, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational
<b>0755T</b>	Digitization of glass microscope slide for level VI, surgical pathology, gross and microscopic examination (List separately in addition to code for primary procedure)	Investigational

<b>0756T</b>	Digitization of glass microscope slides for special stain, including interpretation and report, group I, for microorganisms (eg, acid fast, methenamine silver) (List separately in addition to code for primary procedure)	Investigational
<b>0757T</b>	Digitization of glass microscope slides for special stain, including interpretation and report, group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry (List separately in addition to code for primary procedure)	Investigational
<b>0758T</b>	Digitization of glass microscope slides for special stain, including interpretation and report, histochemical stain on frozen tissue block (List separately in addition to code for primary procedure)	Investigational
<b>0759T</b>	Digitization of glass microscope slides for special stain, including interpretation and report, group III, for enzyme constituents (List separately in addition to code for primary procedure)	Investigational
<b>0760T</b>	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, initial single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational
<b>0761T</b>	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each additional single antibody stain procedure (List separately in addition to code for primary procedure)	Investigational

<b>0762T</b>	Digitization of glass microscope slides for immunohistochemistry or immunocytochemistry, per specimen, each multiplex antibody stain procedure (List separately in addition to code for primary procedure)	Investigational
<b>0763T</b>	Digitization of glass microscope slides for morphometric analysis, tumor immunohistochemistry (eg, Her-2/neu, estrogen receptor/progesterone receptor), quantitative or semiquantitative, per specimen, each single antibody stain procedure, manual (List separately in addition to code for primary procedure)	Investigational
<b>0764T</b>	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to concurrently performed electrocardiogram (List separately in addition to code for primary procedure)	Investigational
<b>0765T</b>	Assistive algorithmic electrocardiogram risk-based assessment for cardiac dysfunction (eg, low-ejection fraction, pulmonary hypertension, hypertrophic cardiomyopathy); related to previously performed electrocardiogram	Investigational
<b>0766T</b>	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; first nerve	Investigational



0767T	Transcutaneous magnetic stimulation by focused low-frequency electromagnetic pulse, peripheral nerve, with identification and marking of the treatment location, including noninvasive electroneurographic localization (nerve conduction localization), when performed; each additional nerve (List separately in addition to code for primary procedure)	Investigational
0770T	Virtual reality technology to assist therapy (List separately in addition to code for primary procedure)	Investigational
0771T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; initial 15 minutes of intraservice time, patient age 5 years or older	Investigational
0772T	Virtual reality (VR) procedural dissociation services provided by the same physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports, requiring the presence of an independent, trained observer to assist in the monitoring of the patient's level of dissociation or consciousness and physiological status; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	Investigational

<b>0773T</b>	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; initial 15 minutes of intraservice time, patient age 5 years or older	Investigational
<b>0774T</b>	Virtual reality (VR) procedural dissociation services provided by a physician or other qualified health care professional other than the physician or other qualified health care professional performing the diagnostic or therapeutic service that the VR procedural dissociation supports; each additional 15 minutes intraservice time (List separately in addition to code for primary service)	Investigational
<b>0776T</b>	Therapeutic induction of intra-brain hypothermia, including placement of a mechanical temperature-controlled cooling device to the neck over carotids and head, including monitoring (eg, vital signs and sport concussion assessment tool 5 [SCAT5]), 30 minutes of treatment	Investigational
<b>0777T</b>	Real-time pressure-sensing epidural guidance system (List separately in addition to code for primary procedure)	Investigational
<b>0778T</b>	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function	Investigational
<b>0779T</b>	Gastrointestinal myoelectrical activity study, stomach through colon, with interpretation and report	Investigational

<b>0780T</b>	Instillation of fecal microbiota suspension via rectal enema into lower gastrointestinal tract	Investigational
<b>0781T</b>	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; bilateral mainstem bronchi	Investigational
<b>0782T</b>	Bronchoscopy, rigid or flexible, with insertion of esophageal protection device and circumferential radiofrequency destruction of the pulmonary nerves, including fluoroscopic guidance when performed; unilateral mainstem bronchus	Investigational
<b>0783T</b>	Transcutaneous auricular neurostimulation, set-up, calibration, and patient education on use of equipment	Investigational
<b>0790T</b>	Revision (eg, augmentation, division of tether), replacement, or removal of thoracolumbar or lumbar vertebral body tethering, including thoracoscopy, when performed	Investigational
<b>0791T</b>	Motor-cognitive, semi-immersive virtual reality-facilitated gait training, each 15 minutes (List separately in addition to code for primary procedure)	Investigational
<b>0792T</b>	Application of silver diamine fluoride 38%, by a physician or other qualified health care professional	Investigational
<b>0793T</b>	Percutaneous transcatheter thermal ablation of nerves innervating the pulmonary arteries, including right heart catheterization, pulmonary artery angiography, and all imaging guidance	Investigational

<b>0794T</b>	Patient-specific, assistive, rules-based algorithm for ranking pharmaco-oncologic treatment options based on the patient's tumor-specific cancer marker information obtained from prior molecular pathology, immunohistochemical, or other pathology results which have been previously interpreted and reported separately	Investigational
<b>0795T</b>	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)	Investigational
<b>0796T</b>	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component (when an existing right ventricular single leadless pacemaker exists to create a dual-chamber leadless pacemaker system)	Investigational

<b>0797T</b>	Transcatheter insertion of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational
<b>0798T</b>	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; complete system (i.e., right atrial and right ventricular pacemaker components)	Investigational
<b>0799T</b>	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right atrial pacemaker component	Investigational
<b>0800T</b>	Transcatheter removal of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational

<b>0801T</b>	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; dual-chamber system (i.e., right atrial and right ventricular pacemaker components)	Investigational
<b>0802T</b>	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right atrial pacemaker component	Investigational
<b>0803T</b>	Transcatheter removal and replacement of permanent dual-chamber leadless pacemaker, including imaging guidance (e.g., fluoroscopy, venous ultrasound, right atrial angiography, right ventriculography, femoral venography) and device evaluation (e.g., interrogation or programming), when performed; right ventricular pacemaker component (when part of a dual-chamber leadless pacemaker system)	Investigational
<b>0804T</b>	Programming device evaluation (in person) with iterative adjustment of implantable device to test the function of device and to select optimal permanent programmed values, with analysis, review, and report, by a physician or other qualified health care professional, leadless pacemaker system in dual cardiac chambers	Investigational

<b>0805T</b>	Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); percutaneous femoral vein approach	Investigational
<b>0806T</b>	Transcatheter superior and inferior vena cava prosthetic valve implantation (i.e., caval valve implantation [CAVI]); open femoral vein approach	Investigational
<b>0807T</b>	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with previously acquired computed tomography (CT) images, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	Investigational
<b>0808T</b>	Pulmonary tissue ventilation analysis using software-based processing of data from separately captured cinefluorograph images; in combination with computed tomography (CT) images taken for the purpose of pulmonary tissue ventilation analysis, including data preparation and transmission, quantification of pulmonary tissue ventilation, data review, interpretation and report	Investigational
<b>0811T</b>	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); setup and patient education on use of equipment	Investigational
<b>0812T</b>	Remote multi-day complex uroflowmetry (eg, calibrated electronic equipment); device supply with automated report generation, up to 10 days	Investigational
<b>0813T</b>	Esophagogastroduodenoscopy, flexible, transoral, with volume adjustment of intragastric bariatric balloon	Investigational

<b>0814T</b>	Percutaneous injection of calcium-based biodegradable osteoconductive material, proximal femur, including imaging guidance, unilateral	Investigational
<b>0815T</b>	Ultrasound-based radiofrequency echographic multi-spectrometry (REMS), bonedensity study and fracture-risk assessment, 1 or more sites, hips, pelvis or spine	Investigational
<b>0820T</b>	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; first physician or other qualified health care professional, each hour	Investigational
<b>0821T</b>	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; second physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)	Investigational
<b>0822T</b>	Continuous in-person monitoring and intervention (eg, psychotherapy, crisis intervention), as needed, during psychedelic medication therapy; clinical staff under the direction of a physician or other qualified health care professional, concurrent with first physician or other qualified health care professional, each hour (List separately in addition to code for primary procedure)	Investigational



<b>0827T</b>	Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; smears with interpretation (List separately in addition to code for primary procedure) (Use 0827T in conjunction with 88104)	Investigational
<b>0828T</b>	Digitization of glass microscope slides for cytopathology, fluids, washings, or brushings, except cervical or vaginal; simple filter method with interpretation (List separately in addition to code for primary procedure) (Use 0828T in conjunction with 88106)	Investigational
<b>0829T</b>	Digitization of glass microscope slides for cytopathology, concentration technique, smears, and interpretation (eg, Saccomanno technique) (List separately in addition to code for primary procedure) (Use 0829T in conjunction with 88108)	Investigational
<b>0830T</b>	Digitization of glass microscope slides for cytopathology, selective-cellular enhancement technique with interpretation (eg, liquid-based slide preparation method), except cervical or vaginal (List separately in addition to code for primary procedure) (Use 0830T in conjunction with 88112)	Investigational
<b>0831T</b>	Digitization of glass microscope slides for cytopathology, cervical or vaginal (any reporting system), requiring interpretation by physician (List separately in addition to code for primary procedure) (Use 0831T in conjunction with 88141)	Investigational

<b>0832T</b>	Digitization of glass microscope slides for cytopathology, smears, any other source; screening and interpretation (List separately in addition to code for primary procedure) (Use 0832T in conjunction with 88160)	Investigational
<b>0833T</b>	Digitization of glass microscope slides for cytopathology, smears, any other source; preparation, screening and interpretation (List separately in addition to code for primary procedure) (Use 0833T in conjunction with 88161)	Investigational
<b>0834T</b>	Digitization of glass microscope slides for cytopathology, smears, any other source; extended study involving over 5 slides and/or multiple stains (List separately in addition to code for primary procedure) (Use 0834T in conjunction with 88162)	Investigational
<b>0835T</b>	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, first evaluation episode, each site (List separately in addition to code for primary procedure) (Use 0835T in conjunction with 88172)	Investigational
<b>0836T</b>	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; immediate cytohistologic study to determine adequacy for diagnosis, each separate additional evaluation episode, same site (List separately in addition to code for primary procedure) (Use 0836T in conjunction with 88177)	Investigational

<b>0837T</b>	Digitization of glass microscope slides for cytopathology, evaluation of fine needle aspirate; interpretation and report (List separately in addition to code for primary procedure) (Use 0837T in conjunction with 88173)	Investigational
<b>0838T</b>	Digitization of glass microscope slides for consultation and report on referred slides prepared elsewhere (List separately in addition to code for primary procedure) (Use 0838T in conjunction with 88321)	Investigational
<b>0839T</b>	Digitization of glass microscope slides for consultation and report on referred material requiring preparation of slides (List separately in addition to code for primary procedure) (Use 0839T in conjunction with 88323)	Investigational
<b>0840T</b>	Digitization of glass microscope slides for consultation, comprehensive, with review of records and specimens, with report on referred material (List separately in addition to code for primary procedure) (Use 0840T in conjunction with 88325)	Investigational
<b>0841T</b>	Digitization of glass microscope slides for pathology consultation during surgery; first tissue block, with frozen section(s), single specimen (List separately in addition to code for primary procedure) (Use 0841T in conjunction with 88331)	Investigational
<b>0842T</b>	Digitization of glass microscope slides for pathology consultation during surgery; each additional tissue block with frozen section(s) (List separately in addition to code for primary procedure) (Use 0842T in conjunction with 88332)	Investigational

<b>0843T</b>	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), initial site (List separately in addition to code for primary procedure) (Use 0843T in conjunction with 88333)	Investigational
<b>0844T</b>	Digitization of glass microscope slides for pathology consultation during surgery; cytologic examination (eg, touch preparation, squash preparation), each additional site (List separately in addition to code for primary procedure) (Use 0844T in conjunction with 88334)	Investigational
<b>0845T</b>	Digitization of glass microscope slides for immunofluorescence, per specimen; initial single antibody stain procedure (List separately in addition to code for primary procedure) (Use 0845T in conjunction with 88346)	Investigational
<b>0846T</b>	Digitization of glass microscope slides for immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure) (Use 0846 <b>Cystourethroscopy, with urethral mechanical dilation and drug delivery by drug-coated balloon catheter</b> T in conjunction with 88350)	Investigational
<b>0847T</b>	Digitization of glass microscope slides for examination and selection of retrieved archival (ie, previously diagnosed) tissue(s) for molecular analysis (eg, KRAS mutational analysis) (List separately in addition to code for primary procedure) (Use 0847T in conjunction with 88363)	Investigational

<b>0848T</b>	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) (Use 0848T in conjunction with 88365)	Investigational
<b>0849T</b>	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) (Use 0849T in conjunction with 88364)	Investigational
<b>0850T</b>	Digitization of glass microscope slides for in situ hybridization (eg, FISH), per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) (Use 0850T in conjunction with 88366)	Investigational
<b>0851T</b>	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; initial single probe stain procedure (List separately in addition to code for primary procedure) (Use 0851T in conjunction with 88368)	Investigational
<b>0852T</b>	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each additional single probe stain procedure (List separately in addition to code for primary procedure) (Use 0852T in conjunction with 88369)	Investigational

<b>0853T</b>	Digitization of glass microscope slides for morphometric analysis, in situ hybridization (quantitative or semiquantitative), manual, per specimen; each multiplex probe stain procedure (List separately in addition to code for primary procedure) (Use 0853T in conjunction with 88377)	Investigational
<b>0854T</b>	Digitization of glass microscope slides for blood smear, peripheral, interpretation by physician with written report (List separately in addition to code for primary procedure) (Use 0854T in conjunction with 85060)	Investigational
<b>0855T</b>	Digitization of glass microscope slides for bone marrow, smear interpretation (List separately in addition to code for primary procedure) (Use 0855T in conjunction with 85097)	Investigational
<b>0856T</b>	Digitization of glass microscope slides for electron microscopy, diagnostic (List separately in addition to code for primary procedure) (Use 0856T in conjunction with 88348)	Investigational
<b>0857T</b>	Opto-acoustic imaging, breast, unilateral, including axilla when performed, realtime with image documentation, augmentative analysis and report (List separately in addition to code for primary procedure) (Use 0857T in conjunction with 76641, 76642)	Investigational
<b>0858T</b>	Externally applied transcranial magnetic stimulation with concomitant measurement of evoked cortical potentials with automated report (Do not report 0858T in conjunction with 95836, 95957, 95961, 95965, 95966)	Investigational

<b>0859T</b>	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), other than for screening for peripheral arterial disease, image acquisition, interpretation, and report; each additional anatomic site (List separately in addition to code for primary procedure)	Investigational
<b>0860T</b>	Noncontact near-infrared spectroscopy (eg, for measurement of deoxyhemoglobin, oxyhemoglobin, and ratio of tissue oxygenation), for screening for peripheral arterial disease, including provocative maneuvers, image acquisition, interpretation, and report, one or both lower extremities	Investigational
<b>0861T</b>	Removal of pulse generator for wireless cardiac stimulator for left ventricular pacing; both components (battery and transmitter)	Investigational
<b>0862T</b>	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; battery component only	Investigational
<b>0863T</b>	Relocation of pulse generator for wireless cardiac stimulator for left ventricular pacing, including device interrogation and programming; transmitter component only	Investigational
<b>0864T</b>	Low-intensity extracorporeal shock wave therapy involving corpus cavernosum, low energy (Do not report 0864T in conjunction with 0101T when treating the same area)	Investigational

<b>0865T</b>	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion identification, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained without diagnostic MRI examination of the brain during the same session (Do not report 0865T in conjunction with 70551, 70552, 70553)	Investigational
<b>0866T</b>	Quantitative magnetic resonance image (MRI) analysis of the brain with comparison to prior magnetic resonance (MR) study(ies), including lesion detection, characterization, and quantification, with brain volume(s) quantification and/or severity score, when performed, data preparation and transmission, interpretation and report, obtained with diagnostic MRI examination of the brain (List separately in addition to code for primary procedure) (Use 0866T in conjunction with 70551, 70552, 70553)	Investigational
<b>0867T</b>	Transperineal laser ablation of benign prostatic hyperplasia, including imaging guidance; prostate volume greater or equal to 50 mL	Investigational
<b>0868T</b>	High-resolution gastric electrophysiology mapping with simultaneous patient-symptom profiling, with interpretation and report	Investigational



<b>0870T</b>	Implantation of subcutaneous peritoneal ascites pump system, percutaneous, including pump-pocket creation, insertion of tunneled indwelling bladder and peritoneal catheters with pump connections, including all imaging and initial programming, when performed	Investigational
<b>0871T</b>	Replacement of a subcutaneous peritoneal ascites pump, including reconnection between pump and indwelling bladder and peritoneal catheters, including initial programming and imaging, when performed	Investigational
<b>0872T</b>	Replacement of indwelling bladder and peritoneal catheters, including tunneling of catheter(s) and connection with previously implanted peritoneal ascites pump, including imaging and programming, when performed	Investigational
<b>0873T</b>	Revision of a subcutaneously implanted peritoneal ascites pump system, any component (ascites pump, associated peritoneal catheter, associated bladder catheter), including imaging and programming, when performed	Investigational
<b>0874T</b>	Removal of a peritoneal ascites pump system, including implanted peritoneal ascites pump and indwelling bladder and peritoneal catheters	Investigational
<b>0875T</b>	Programming of subcutaneously implanted peritoneal ascites pump system by physician or other qualified health care professional	Investigational
<b>0876T</b>	Duplex scan of hemodialysis fistula, computer-aided, limited (volume flow, diameter, and depth, including only body of fistula)	Investigational

<b>0877T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained without concurrent CT examination of any structure contained in previously acquired diagnostic imaging	Investigational
<b>0878T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; obtained with concurrent CT examination of the same structure	Investigational
<b>0879T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; radiological data preparation and transmission	Investigational
<b>0880T</b>	Augmentative analysis of chest computed tomography (CT) imaging data to provide categorical diagnostic subtype classification of interstitial lung disease; physician or other qualified health care professional interpretation and report	Investigational
<b>0881T</b>	Cryotherapy of the oral cavity using temperature regulated fluid cooling system, including placement of an oral device, monitoring of patient tolerance to treatment, and removal of the oral device	Investigational
<b>0882T</b>	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; initial nerve (List separately in addition to code for primary procedure)	Investigational

<b>0883T</b>	Intraoperative therapeutic electrical stimulation of peripheral nerve to promote nerve regeneration, including lead placement and removal, upper extremity, minimum of 10 minutes; each additional nerve (List separately in addition to code for primary procedure)	Investigational
<b>0884T</b>	Esophagoscopy, flexible, transoral, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for esophageal stricture, including fluoroscopic guidance, when performed	Investigational
<b>0885T</b>	Colonoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed	Investigational
<b>0886T</b>	Sigmoidoscopy, flexible, with initial transendoscopic mechanical dilation (eg, nondrug-coated balloon) followed by therapeutic drug delivery by drug-coated balloon catheter for colonic stricture, including fluoroscopic guidance, when performed	Investigational
<b>0887T</b>	End-tidal control of inhaled anesthetic agents and oxygen to assist anesthesia care delivery (List separately in addition to code for primary procedure)	Investigational
<b>0888T</b>	Histotripsy (ie, non-thermal ablation via acoustic energy delivery) of malignant renal tissue, including imaging guidance	Investigational

<b>0889T</b>	Personalized target development for accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation derived from a structural and resting-state functional MRI, including data preparation and transmission, generation of the target, motor threshold-starting location, neuronavigation files and target report, review and interpretation	Investigational
<b>0890T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including target assessment, initial motor threshold determination, neuronavigation, delivery and management, initial treatment day	Investigational
<b>0891T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent treatment day	Investigational
<b>0892T</b>	Accelerated, repetitive high-dose functional connectivity MRI-guided theta-burst stimulation, including neuronavigation, delivery and management, subsequent motor threshold redetermination with delivery and management, per treatment day	Investigational
<b>0893T</b>	Noninvasive assessment of blood oxygenation, gas exchange efficiency, and cardiorespiratory status, with physician or other qualified health care professional interpretation and report	Investigational
<b>0894T</b>	Cannulation of the liver allograft in preparation for connection to the normothermic perfusion device and decannulation of the liver allograft following normothermic perfusion	Investigational

<p><b>0895T</b></p>	<p>Connection of liver allograft to normothermic machine perfusion device, hemostasis control; initial 4 hours of monitoring time, including hourly physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment)</p>	<p>Investigational</p>
<p><b>0896T</b></p>	<p>Connection of liver allograft to normothermic machine perfusion device, hemostasis control; each additional hour, including physiological and laboratory assessments (eg, perfusate temperature, perfusate pH, hemodynamic parameters, bile production, bile pH, bile glucose, biliary bicarbonate, lactate levels, macroscopic assessment) (List separately in addition to code for primary procedure)</p>	<p>Investigational</p>
<p><b>0897T</b></p>	<p>Noninvasive augmentative arrhythmia analysis derived from quantitative computational cardiac arrhythmia simulations, based on selected intervals of interest from 12-lead electrocardiogram and uploaded clinical parameters, including uploading clinical parameters with interpretation and report</p>	<p>Investigational</p>
<p><b>0898T</b></p>	<p>Noninvasive prostate cancer estimation map, derived from augmentative analysis of image-guided fusion biopsy and pathology, including visualization of margin volume and location, with margin determination and physician interpretation and report</p>	<p>Investigational</p>

<b>0899T</b>	Noninvasive determination of absolute quantitation of myocardial blood flow (AQMBF), derived from augmentative algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)	Investigational
<b>0900T</b>	Noninvasive estimate of absolute quantitation of myocardial blood flow (AQMBF), derived from assistive algorithmic analysis of the dataset acquired via contrast cardiac magnetic resonance (CMR), pharmacologic stress, with interpretation and report by a physician or other qualified health care professional (List separately in addition to code for primary procedure)	Investigational
<b>20560</b>	Needle insertion(s) without injection(s); 1 or 2 muscle(s)	Investigational
<b>20561</b>	Needle insertion(s) without injection(s); 3 or more muscles	Investigational
<b>22526</b>	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; single level	Investigational
<b>22527</b>	Percutaneous intradiscal electrothermal annuloplasty, unilateral or bilateral including fluoroscopic guidance; 1 or more additional levels (List separately in addition to code for primary procedure)	Investigational
<b>22836</b>	Vertebral body tethering; up to 7 vertebral segments	Investigational
<b>22837</b>	Vertebral body tethering; 8 or more vertebral segments	Investigational
<b>22838</b>	Revision, replacement, or removal of vertebral body tethering	Investigational

<b>22857</b>	Total disc arthroplasty (artificial disc), anterior approach, including discectomy to prepare interspace (other than for decompression), single interspace, lumbar	Investigational
<b>22860</b>	Total disc arthroplasty, anterior approach, including discectomy ; second lumbar interspace	Investigational
<b>22862</b>	Revision including replacement of total disc arthroplasty (artificial disc), anterior approach, single interspace; lumbar	Investigational
<b>22867</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; single level	Investigational
<b>22868</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without fusion, including image guidance when performed, with open decompression, lumbar; second level (List separately in addition to code for primary procedure)	Investigational
<b>22869</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; single level	Investigational
<b>22870</b>	Insertion of interlaminar/interspinous process stabilization/distraction device, without open decompression or fusion, including image guidance when performed, lumbar; second level (List separately in addition to code for primary procedure)	Investigational
<b>27278</b>	Arthrodesis, sacroiliac joint, percutaneous, with image guidance, including placement of intra-articular implant(s) (eg, bone allograft[s], synthetic device[s]), without placement of transfixation device	Investigational

<b>28890</b>	Extracorporeal shock wave, high energy, performed by a physician or other qualified health care professional, requiring anesthesia other than local, including ultrasound guidance, involving the plantar fascia	Investigational
<b>30468</b>	Repair of nasal valve collapse with subcutaneous/submucosal lateral wall implant(s)	Investigational
<b>30469</b>	Nasal valve collapse repair using low energy, temperature-controlled remodeling	Investigational
<b>31242</b>	Surgical nasal/sinus endoscopy; radiofrequency ablation, posterior nasal nerve	Investigational
<b>31243</b>	Surgical nasal/sinus endoscopy; cryoablation, posterior nasal nerve	Investigational
<b>31647</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), initial lobe	Investigational
<b>31648</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), initial lobe	Investigational
<b>31649</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with removal of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure)	Investigational
<b>31651</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with balloon occlusion, when performed, assessment of air leak, airway sizing, and insertion of bronchial valve(s), each additional lobe (List separately in addition to code for primary procedure[s])	Investigational
<b>31660</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 1 lobe	Investigational



<b>31661</b>	Bronchoscopy, rigid or flexible, including fluoroscopic guidance, when performed; with bronchial thermoplasty, 2 or more lobes	Investigational
<b>33275</b>	Transcatheter removal of permanent leadless pacemaker, right ventricular, including imaging guidance (eg, fluoroscopy, venous ultrasound, ventriculography, femoral venography), when performed	Investigational
<b>33276</b>	Phrenic nerve stimulator system placement, initial analysis with diagnostic mode activation, when performed	Investigational
<b>33277</b>	Phrenic nerve stimulator transvenous lead placement (List separately in addition to code for primary procedure)	Investigational
<b>33278</b>	Phrenic nerve stimulator removal	Investigational
<b>33279</b>	Phrenic nerve stimulator removal; transvenous stimulation or sensing lead(s) only	Investigational
<b>33280</b>	Phrenic nerve stimulator removal; pulse generator only	Investigational
<b>33281</b>	Phrenic nerve stimulator transvenous lead repositioning	Investigational
<b>33287</b>	Phrenic nerve stimulator, removal and replacement; pulse generator	Investigational
<b>33288</b>	Phrenic nerve stimulator removal and replacement; transvenous stimulation or sensing lead	Investigational
<b>33289</b>	Transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed	Investigational

<b>33370</b>	Transcatheter placement and subsequent removal of cerebral embolic protection device(s), including arterial access, catheterization, imaging, and radiological supervision and interpretation, percutaneous (List separately in addition to code for primary procedure)	Investigational
<b>33548</b>	Surgical ventricular restoration procedure, includes prosthetic patch, when performed (eg, ventricular remodeling, SVR, SAVER, Dor procedures)	Investigational
<b>36473</b>	Endovenous ablation therapy of incompetent vein, extremity, inclusive of all imaging guidance and monitoring, percutaneous, mechanochemical; first vein treated	Investigational
<b>36474</b>	Subsequent vein(s) treated in a single extremity, each through separate access sites (List separately in addition to code for primary procedure)	Investigational
<b>36836</b>	Upper extremity, single access percutaneous arteriovenous fistula creation	Investigational
<b>36837</b>	Upper extremity, separate access percutaneous arteriovenous fistula creation	Investigational
<b>41512</b>	Tongue base suspension, permanent suture technique	Investigational
<b>43206</b>	Esophagoscopy, flexible, transoral; with optical endomicroscopy	Investigational
<b>43252</b>	Esophagogastroduodenoscopy, flexible, transoral; with optical endomicroscopy	Investigational
<b>43284</b>	Laparoscopy, surgical, esophageal sphincter augmentation procedure, placement of sphincter augmentation device (ie, magnetic band), including cruroplasty when performed	Investigational
<b>43285</b>	Removal of esophageal sphincter augmentation device	Investigational
<b>43290</b>	Esophagogastroduodenoscopy, with deployment of balloon	Investigational

<b>43291</b>	Esophagogastroduodenoscopy, with removal of balloon	Investigational
<b>43497</b>	Lower esophageal myotomy, transoral (ie, peroral endoscopic myotomy [POEM])	Investigational
<b>43647</b>	Laparoscopy, surgical; implantation or replacement of gastric neurostimulator electrodes, antrum	Investigational
<b>43648</b>	Laparoscopy, surgical; revision or removal of gastric neurostimulator electrodes, antrum	Investigational
<b>43881</b>	Implantation or replacement of gastric neurostimulator electrodes, antrum, open	Investigational
<b>43882</b>	Revision or removal of gastric neurostimulator electrodes, antrum, open	Investigational
<b>46707</b>	Repair of anorectal fistula with plug (eg, porcine small intestine submucosa [SIS])	Investigational
<b>47371</b>	Laparoscopy, surgical, ablation of 1 or more liver tumor(s); cryosurgical	Investigational
<b>47381</b>	Ablation, open, of 1 or more liver tumor(s); cryosurgical	Investigational
<b>47383</b>	Ablation, 1 or more liver tumor(s), percutaneous, cryoablation	Investigational
<b>52284</b>	Cystourethroscopy, with urethral mechanical dilation and drug delivery by drug-coated balloon catheter	Investigational
<b>53451</b>	Periurethral transperineal adjustable balloon continence device; bilateral insertion, including cystourethroscopy and imaging guidance	Investigational
<b>53452</b>	Periurethral transperineal adjustable balloon continence device; unilateral insertion, including cystourethroscopy and imaging guidance	Investigational
<b>53453</b>	Periurethral transperineal adjustable balloon continence device; removal, each balloon	Investigational
<b>53454</b>	Periurethral transperineal adjustable balloon continence device; percutaneous adjustment of balloon(s) fluid volume	Investigational

<b>55706</b>	Biopsies, prostate, needle, transperineal, stereotactic template guided saturation sampling, including imaging guidance	Investigational
<b>55880</b>	Ablation of malignant prostate tissue, transrectal, with high intensity-focused ultrasound (HIFU), including ultrasound guidance	Investigational
<b>61736</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; single trajectory for 1 simple lesion	Investigational
<b>61737</b>	Laser interstitial thermal therapy (LITT) of lesion, intracranial, including burr hole(s), with magnetic resonance imaging guidance, when performed; multiple trajectories for multiple or complex lesion(s)	Investigational
<b>62263</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 2 or more days	Investigational
<b>62264</b>	Percutaneous lysis of epidural adhesions using solution injection (eg, hypertonic saline, enzyme) or mechanical means (eg, catheter) including radiologic localization (includes contrast when administered), multiple adhesiolysis sessions; 1 day	Investigational
<b>62287</b>	Decompression procedure, percutaneous, of nucleus pulposus of intervertebral disc, any method utilizing needle based technique to remove disc material under fluoroscopic imaging or other form of indirect visualization, with discography and/or epidural injection(s) at the treated level(s), when performed, single or multiple levels, lumbar	Investigational

<b>62380</b>	Endoscopic decompression of spinal cord, nerve root(s), including laminotomy, partial facetectomy, foraminotomy, discectomy and/or excision of herniated intervertebral disc, 1 interspace, lumbar	Investigational
<b>64454</b>	Injection(s), anesthetic agent(s) and/or steroid; genicular nerve branches, including imaging guidance, when performed	Investigational
<b>64505</b>	Injection, anesthetic agent; sphenopalatine ganglion	Investigational
<b>64575</b>	Open implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)	Investigational
<b>64585</b>	Revision or removal of peripheral neurostimulator electrode array	Investigational
<b>64624</b>	Destruction by neurolytic agent, genicular nerve branches including imaging guidance, when performed	Investigational
<b>64625</b>	Radiofrequency ablation, nerves innervating the sacroiliac joint, with image guidance (ie, fluoroscopy or computed tomography)	Investigational
<b>64628</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; first 2 vertebral bodies, lumbar or sacral	Investigational
<b>64629</b>	Thermal destruction of intraosseous basivertebral nerve, including all imaging guidance; each additional vertebral body, lumbar or sacral (List separately in addition to code for primary procedure)	Investigational
<b>76120</b>	Cineradiography/videoradiography, except where specifically included	Investigational
<b>76125</b>	Cineradiography/videoradiography to complement routine examination (List separately in addition to code for primary procedure)	Investigational
<b>77085</b>	Dual-energy X-ray absorptiometry (DXA), bone density study, 1 or more sites; axial skeleton (eg, hips, pelvis, spine), including vertebral fracture assessment	Investigational

<b>77086</b>	Vertebral fracture assessment via dual-energy X-ray absorptiometry (DXA)	Investigational
<b>77089</b>	Trabecular bone score (TBS), structural condition of the bone microarchitecture; using dual X-ray absorptiometry (DXA) or other imaging data on gray-scale variogram, calculation, with interpretation and report on fracture-risk	Investigational
<b>77090</b>	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical preparation and transmission of data for analysis to be performed elsewhere	Investigational
<b>77091</b>	Trabecular bone score (TBS), structural condition of the bone microarchitecture; technical calculation only	Investigational
<b>77092</b>	Trabecular bone score (TBS), structural condition of the bone microarchitecture; interpretation and report on fracture-risk only by other qualified health care professional	Investigational
<b>78835</b>	Radiopharmaceutical quantification measurement(s) single area (List separately in addition to code for primary procedure)	Investigational
<b>81277</b>	Cytogenomic neoplasia (genome-wide) microarray analysis, interrogation of genomic regions for copy number and loss-of-heterozygosity variants for chromosomal abnormalities	Investigational
<b>81418</b>	Drug metabolism genomic sequence panel, must include testing of at least 6 genes, including CYP2C19, CYP2D6, and CYP2D6 duplications and deletions	Investigational
<b>81449</b>	Targeted genomic sequence analysis panel, solid organ neoplasm, 5-50 genes RNA analysis	Investigational

<b>81451</b>	Hematolymphoid neoplasm or disorder, genomic sequence analysis panel, 5-50 genes, interrogation for sequence variants, and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	Investigational
<b>81456</b>	Solid organ or hematolymphoid neoplasm or disorder, 51 or greater genes, genomic sequence analysis panel, interrogation for sequence variants and copy number variants or rearrangements, or isoform expression or mRNA expression levels, if performed; RNA analysis	Investigational
<b>81514</b>	Infectious disease, bacterial vaginosis and vaginitis, quantitative real-time amplification of DNA markers for Gardnerella vaginalis, Atopobium vaginae, Megasphaera type 1, Bacterial Vaginosis Associated Bacteria-2 (BVAB-2), and Lactobacillus species (L. crispatus and L. jensenii), utilizing vaginal-fluid specimens, algorithm reported as a positive or negative for high likelihood of bacterial vaginosis, includes separate detection of Trichomonas vaginalis and/or Candida species (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis), Candida glabrata, Candida krusei, when reported	Investigational
<b>81539</b>	Oncology (high-grade prostate cancer), biochemical assay of four proteins (Total PSA, Free PSA, Intact PSA, and human kallikrein-2 [hK2]), utilizing plasma or serum, prognostic algorithm reported as a probability score	Investigational

<b>81560</b>	Transplantation medicine (allograft rejection, pediatric liver and small bowel), measurement of donor and third party-induced CD154+T-cytotoxic memory cells, utilizing whole peripheral blood, algorithm reported as a rejection risk score	Investigational
<b>82107</b>	Alpha-fetoprotein (AFP); AFP-L3 fraction isoform and total AFP (including ratio)	Investigational
<b>82172</b>	Apolipoprotein, each	Investigational
<b>82523</b>	Collagen cross links, any method	Investigational
<b>82610</b>	Cystatin C	Investigational
<b>82664</b>	Electrophoretic technique, not elsewhere specified	Investigational
<b>83006</b>	Growth stimulation expressed gene 2 (ST2, Interleukin 1 receptor like-1)	Investigational
<b>83695</b>	Lipoprotein (a)	Investigational
<b>83722</b>	Lipoprotein, direct measurement; small dense LDL cholesterol	Investigational
<b>83937</b>	Osteocalcin (bone g1a protein)	Investigational
<b>83987</b>	pH; exhaled breath condensate	Investigational
<b>84080</b>	Phosphatase, alkaline; isoenzymes	Investigational
<b>86305</b>	Human epididymis protein 4 (HE4)	Investigational
<b>86352</b>	Cellular function assay involving stimulation (eg, mitogen or antigen) and detection of biomarker (eg, ATP)	Investigational
<b>88375</b>	Optical endomicroscopic image(s), interpretation and report, real-time or referred, each endoscopic session	Investigational
<b>90584</b>	Dengue vaccine, quadrivalent, live, 2 dose schedule, for subcutaneous use	Investigational
<b>90637</b>	Influenza virus vaccine, quadrivalent (qIRV), mRNA; 30 mcg/0.5 mL dosage, for intramuscular use	Investigational
<b>90638</b>	Influenza virus vaccine, quadrivalent (qIRV), mRNA; 60 mcg/0.5 mL dosage, for intramuscular use	Investigational
<b>91111</b>	Gastrointestinal tract imaging, intraluminal (eg, capsule endoscopy), esophagus with interpretation and report	Investigational



<b>91300</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3mL dosage, diluent reconstituted, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91301</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 100 mcg/0.5mL dosage, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91303</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, DNA, spike protein, adenovirus type 26 (Ad26) vector, preservative free, 5x10 <sup>10</sup> viral particles/0.5mL dosage, for intramuscular use	Investigational COVID-19 Effective:(05/07/2023)
<b>91305</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, tris-sucrose formulation, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91306</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.25 mL dosage, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91307</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 10 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)

<b>91308</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91309</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 50 mcg/0.5 mL dosage, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>91311</b>	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 25 mcg/0.25 mL dosage, for intramuscular use	Investigational COVID-19 Effective:(04/18/2023)
<b>92145</b>	Corneal hysteresis determination, by air impulse stimulation, unilateral or bilateral, with interpretation and report	Investigational
<b>92548</b>	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report;	Investigational
<b>92549</b>	Computerized dynamic posturography sensory organization test (CDP-SOT), 6 conditions (ie, eyes open, eyes closed, visual sway, platform sway, eyes closed platform sway, platform and visual sway), including interpretation and report; with motor control test (MCT) and adaptation test (ADT)	Investigational
<b>92572</b>	Staggered spondaic word test	Investigational
<b>92576</b>	Synthetic sentence identification test	Investigational
<b>92972</b>	Coronary transluminal lithotripsy	Investigational

<b>93050</b>	Arterial pressure waveform analysis for assessment of central arterial pressures, includes obtaining waveform(s), digitization and application of nonlinear mathematical transformations to determine central arterial pressures and augmentation index, with interpretation and report, upper extremity artery, non-invasive	Investigational
<b>93150</b>	Therapy activation of phrenic nerve stimulator system	Investigational
<b>93151</b>	Interrogation and programming of phrenic nerve stimulator system	Investigational
<b>93152</b>	Interrogation and programming of phrenic nerve stimulator system done at the same time as a polysomnography	Investigational
<b>93153</b>	Interrogation without programming of phrenic nerve stimulator system	Investigational
<b>93264</b>	Remote monitoring of a wireless pulmonary artery pressure sensor for up to 30 days, including at least weekly downloads of pulmonary artery pressure recordings, interpretation(s), trend analysis, and report(s) by a physician or other qualified health care professional	Investigational
<b>93356</b>	Myocardial strain imaging using speckle tracking-derived assessment of myocardial mechanics (List separately in addition to codes for echocardiography imaging)	Investigational
<b>93701</b>	Bioimpedance-derived physiologic cardiovascular analysis	Investigational
<b>95012</b>	Nitric oxide expired gas determination	Investigational
<b>95803</b>	Actigraphy testing, recording, analysis, interpretation, and report (minimum of 72 hours to 14 consecutive days of recording)	Investigational

<b>95905</b>	Motor and/or sensory nerve conduction, using preconfigured electrode array(s), amplitude and latency/velocity study, each limb, includes F-wave study when performed, with interpretation and report	Investigational
<b>95957</b>	Digital analysis of electroencephalogram (EEG) (eg, for epileptic spike analysis)	Investigational
<b>96000</b>	Comprehensive computer-based motion analysis by videotaping and 3D kinematics;	Investigational
<b>96001</b>	Comprehensive computer-based motion analysis by videotaping and 3D kinematics; with dynamic plantar pressure measurements during walking	Investigational
<b>96002</b>	Dynamic surface electromyography, during walking or other functional activities, 1-12 muscles	Investigational
<b>96003</b>	Dynamic fine wire electromyography, during walking or other functional activities, 1 muscle	Investigational
<b>96004</b>	Review and interpretation by physician or other qualified health care professional of comprehensive computer-based motion analysis, dynamic plantar pressure measurements, dynamic surface electromyography during walking or other functional activities, and dynamic fine wire electromyography, with written report	Investigational
<b>97033</b>	Application of a modality to 1 or more areas; iontophoresis, each 15 minutes	Investigational
<b>97533</b>	Sensory integrative techniques to enhance sensory processing and promote adaptive responses to environmental demands, direct (one-on-one) patient contact, each 15 minutes	Investigational
<b>97610</b>	Low frequency, non-contact, non-thermal ultrasound, including topical application(s), when performed, wound assessment, and instruction(s) for ongoing care, per day	Investigational

<b>97799</b>	Unlisted physical medicine/rehabilitation service or procedure	Investigational
<b>98978</b>	Remote therapeutic monitoring; device supply, recording, transmission to monitor cognitive behavioral therapy, each 30 days	Investigational